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The aims of this research were to determine how gene expression and chronic 
obstructive pulmonary disease (COPD) susceptibility are related to antioxidant 
nutritional status and to determine if antioxidant supplementation prevents 
COPD disease processes. Although cigarette smoking is the primary risk 
factor for COPD a minority of smokers develop disease thus other factors 
must play a role in disease susceptibility and progression. The studies 
conducted for this dissertation address the hypotheses that dietary 
supplementation with antioxidant vitamins can augment the lung’s antioxidant 
defenses thereby preventing disease development and that antioxidant-related 
genes are dysregulated by COPD disease processes. The first project was a 
large-scale randomized clinical intervention trial of vitamin E dietary 
supplements in which the association of supplementation and risk of COPD 
was assessed. Women randomly assigned to take vitamin E supplements 
during a 10-year intervention were 10% less likely to develop COPD during the 
study period. The effect of the intervention was similar in both smokers and 
non-smokers and was not changed by other factors measured in the study. 
The second study was a small-scale clinical intervention trial that investigated 
how antioxidant supplementation altered concentrations of nutrients 
systemically and in the lung compartment. For intervention trials assessing 
whether the supplement is reaching the target tissue is critical and no prior 
studies show direct evidence that supplemental antioxidants reach the lung. In 
this study bronchioalveolar lavage fluid concentrations of vitamin E and 
selenium were measured before and after intervention with vitamins E and C 
and selenium and nutrient concentration increased in response to 
supplementation, providing evidence that antioxidant supplements were 
delivered to the lung where they could combat oxidative stress that causes 
lung tissue damage. The third study assessed antioxidant status in plasma 
and lung tissue and gene expression in lung tissue of COPD patients with 
different levels of disease severity. Twelve antioxidant-related genes were 
differentially expressed in patients with more severe disease. Taken together 
the findings from these studies suggest that intervention with antioxidant 
nutrients increases lung nutrient status and decreases COPD risk and the 
mechanism may be in part modulation of antioxidant-related gene expression.  
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CHAPTER 1 
INTRODUCTION 
 
Chronic obstructive pulmonary disease, comprised of emphysema and 
chronic bronchitis, is a major cause of morbidity and mortality, and is 
characterized by irreversible airflow limitation.(1) Symptoms of COPD include 
recurrent respiratory infections, severe cough, and poor overall oxygenation, 
and at advanced stages COPD commonly progresses to respiratory failure 
and death. COPD is the fourth leading cause of mortality in the US.(2) The 
public health burden of COPD worldwide is growing and in 1998 the Global 
Burden of Disease study predicted that COPD will increase from the 12th to the 
5th leading cause of disease burden by 2020.(3) The single most important risk 
factor for the development of COPD is exposure to cigarette smoke, with 
current or former smokers constituting 80-90% of COPD patients.(4-6) Despite 
the clear importance of smoking in the etiology of disease, there is 
considerable variation among smokers in their response to cigarette smoke 
exposure. A large cross-sectional study found that only an estimated 15% of 
the variation in lung function was explained by smoking parameters.(7) While 
not discounting the paramount importance of cigarette smoke exposure in the 
development of COPD, clearly other as yet undiscovered factors are important 
in disease.  
The current understanding of COPD pathogenesis suggests a role for 
exaggerated inflammatory response, protease/antiprotease imbalance, and 
oxidant/antioxidant imbalance in disease susceptibility. This dissertation 
focused on oxidant/antioxidant imbalance for the following reasons: firstly, a 
single puff of cigarette smoke contains 1014 radicals and upon contact with the 
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large surface area of the lung immediately increases the strain on the 
antioxidant defenses.(8) When antioxidant defenses are overwhelmed, 
oxidative stress can provoke and enhance both the inflammation and the 
antiprotease inactivation that are associated with COPD as well as directly 
contributing to lung tissue damage. Secondly, antioxidant defenses are a 
compelling COPD research target because they offer the possibility of simple 
and inexpensive interventions. Finally, observational epidemiologic studies of 
antioxidants and lung outcomes suggest antioxidants have lung-protective 
properties. 
Observational epidemiological studies of dietary antioxidant intake, 
serum antioxidant concentration, and lung outcomes suggest that lower levels 
of antioxidant defense are associated with decreased lung function 
 and higher COPD mortality risk.(9-15) Although a number of studies have 
investigated the role of antioxidant supplements to prevent COPD only nine 
randomized controlled trials have been conducted and in each of these COPD 
was a secondary outcome and the antioxidants studied included vitamins E, C, 
and beta-carotene and N-acetylcysteine; the majority of studies investigated 
N-acetylcysteine.(16-23) Prior to this dissertation no clinical trials had 
assessed the effect of vitamin E supplementation on the primary prevention of 
COPD. One randomized controlled trial of alpha-tocopherol and beta-carotene 
found no effect of supplements on COPD symptoms, but the prevalence of 
COPD at study baseline (prior to intervention) was inversely associated with 
dietary and serum concentrations of both antioxidants.(20) In a trial where 
subjects with coronary or occlusive arterial disease or diabetes were 
supplemented with vitamins E and C and beta-carotene no significant 
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difference in measures of pulmonary function or number of hospitalizations 
was seen between the supplemented and placebo groups.(23)  
Gene expression patterns offer a snapshot into an individual’s adaptive 
response to a particular exposure, such as smoking. Expression values are a 
summative measure of all stimuli that promote and suppress transcription, and 
thus, represent the cellular environment at the time of the assay. In this way, 
expression patterns represent the amount of oxidant exposure and the level of 
antioxidant defense together as the “dose” of oxidative stress that reaches the 
cell in a particular individual. Smokers exhibit altered gene expression 
compared with nonsmokers and these altered expression patterns are 
expected to precede biochemical and tissue changes on the pathway to 
disease development, thus identifying interventions that are successful at the 
level of transcription will provide strong support for their success as disease 
preventives or treatments.  
The scientific objective of this dissertation is to investigate nutritional, 
genetic, and environmental factors that increase susceptibility to and/or 
severity of chronic obstructive pulmonary disease (COPD).  Three projects 
were completed as follows: 1) a randomized study of vitamin E 
supplementation and risk of chronic lung disease in the Women’s Health 
Study, which was a post hoc analysis of the incidence of COPD and asthma in 
a double-blinded randomized clinical trial of vitamin E and aspirin in women, 2) 
a study of the effect of supplementary antioxidant vitamins on plasma and 
airway lining fluid in cigarette smokers, which was a double-blinded 
randomized clinical trial investigating the effect of dietary antioxidant 
supplements in the lung compartment (hereafter referred to as ExSEL, for 
Expression effects of selenium and vitamin E in lung), and 3)  a study of the 
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differential expression of vitamin E and selenium-responsive genes by disease 
severity in chronic obstructive pulmonary disease (hereafter referred to as 
LTRC, given the Lung Tissue Research Consortium source of these samples), 
which was a small study of antioxidant concentrations in plasma and lung 
tissue in relation to gene expression in lung tissue of COPD patients at varying 
levels of disease severity.  
A molecular epidemiologic model is presented below, showing the 
purported exposure leading to a biomarker of disease outcome, which in turn 
leads to disease onset and/or progression.  This model provides a framework 
for understanding how the three proposed projects integrate to form a 
complementary and inclusive investigation into COPD, its risk factors and 
biomarkers, and potential dietary and supplementation intervention strategies, 
including the effect of supplementation on gene expression. 
 
 
Figure 1.1 Molecular epidemiologic model for risk factors 
 and biomarkers leading to COPD. 
 
Under this framework no single project addressed all aspects of the 
molecular epidemiologic model, but in combination the projects provide a 
comprehensive study of the model.  The data from the Women’s Health Study 
provided a large and comprehensive study of exposure to supplemental 
vitamin E and its association with COPD onset, but biomarker information was 
unavailable. ExSEL was designed to address how antioxidant 
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supplementation alters systemic and lung-compartment concentrations of 
antioxidants.  ExSEL was not designed to investigate COPD as an outcome 
because its time-course was far too short for such a determination.  The 
analysis of lung tissue and plasma concentrations of antioxidants and lung 
tissue gene expression in samples from COPD patients provided insight into 
how antioxidants concentrations differ by disease severity, and how those 
differences are related to gene expression, providing clues as to the role of 
antioxidant status in disease progression. By integrating these three studies a 
complete model of COPD risk factors, biomarkers, and outcomes emerged 
with each study contributing an essential piece to the overall understanding of 
how antioxidants and gene expression are related to COPD risk and 
progression. 
 
 
Figure 1.2 Integration of dissertation projects in the molecular epidemiologic 
model for risk factors and biomarkers leading to COPD; WHS=Women’s 
Health Study; ExSEL= Expression Effects of Selenium and Vitamin E in Lung 
Study; LTRC=Lung Tissue Research Consortium Study. 
 
The complementary nature of the three proposed projects provided a 
substantial, well-integrated study of COPD that contributed meaningful new 
information to the scientific body of knowledge about COPD, its causation and 
the joint and separate roles of nutrition, gender and lifestyle. 
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CHAPTER 2 
RANDOMISED VITAMIN E SUPPLEMENTATION AND RISK OF  
CHRONIC LUNG DISEASE IN THE WOMEN’S HEALTH STUDY* 
 
 
Abstract 
Background: The oxidant/antioxidant balance in lung tissue is hypothesised 
to contribute to chronic obstructive pulmonary disease (COPD) risk. 
Observational studies consistently report higher antioxidant status associated 
with lower COPD risk, but few randomised studies have been reported.  
Methods: A post-hoc analysis of 38,597 women without chronic lung disease 
at baseline was conducted in the Women’s Health Study (WHS) to test the 
effect of vitamin E on risk of incident chronic lung disease. The WHS was a 
randomised, double-blind, placebo-controlled, factorial trial of vitamin E (600 
IU every other day) and aspirin (100 mg every other day) in female health 
professionals aged ≥45. Using Cox proportional hazards models, the effect of 
randomised vitamin E assignment on self-reported, physician-diagnosed 
chronic lung disease was evaluated.  
Results: During 10 years of follow-up (376,710 person-years), 760 first 
occurrences of chronic lung disease were reported in the vitamin E arm 
compared to 846 in the placebo arm (Hazard Ratio [HR] 0.90; 95% confidence 
interval [CI] 0.81-0.99; p=0.029). This 10% reduction in the risk of incident  
 
*Agler AH, Kurth T, Gaziano JM, Buring JE, Cassano PA. Randomised vitamin 
E supplementation and risk of chronic lung disease in the Women’s Health 
Study. Thorax January 21, 2011; doi: 10.1136/thx.2010.155028. 
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chronic lung disease was not modified by cigarette smoking, age, randomised 
aspirin assignment, multivitamin use, or dietary vitamin E intake (minimum P 
for interaction = 0.19). Current cigarette smoking was a strong predictor of 
chronic lung disease risk (HR 4.17; 95% CI 3.70-4.70; versus never smokers).  
Conclusions: In this large, randomised trial, assignment to 600 IU of vitamin 
E led to a 10% reduction in the risk of chronic lung disease in women. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is characterised by 
progressive, irreversible airflow limitation and comprises a significant public 
health burden, with increasing trends in incidence and prevalence.(1) COPD 
prevalence in the U.S. adult population is 3-4% and, worldwide COPD 
prevalence is about 10%.(1;2) COPD was the 5th leading cause of death in the 
U.S. in 2001 and is expected to become the 3rd leading cause of death by 
2020, largely due to population ageing and increasing cumulative cigarette 
smoke exposure, the primary risk factor for COPD.(1;3)  
Factors that may contribute to rising COPD incidence include: obesity, 
dietary patterns, environmental and occupational exposures, and improved 
diagnostic and screening programmes.(1;4-6)  Several lines of evidence 
support the hypothesis that diet plays a role in COPD aetiology.(4;6;7) 
Observational studies of diet or nutritional status biomarkers and randomised 
trials of diet or nutritional supplements have investigated the relation of 
antioxidants, notably vitamin E, and lung outcomes. Observational studies 
investigating the association of dietary intake and pulmonary function 
consistently report that higher intake of nutrients with antioxidant properties is 
associated with better pulmonary outcomes, but causal inferences are limited 
by concerns about confounding and other biases.(8;9) Studies comparing 
COPD patients to healthy individuals report lower plasma and peripheral 
skeletal muscle vitamin E (α−tocopherol) concentrations in patients, and a 
lower risk of death from respiratory disease with higher serum α-tocopherol 
concentration, but whether nutrition contributed to the onset of COPD is less 
clear.(10-12)  
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Randomised trials of diet change or vitamin E supplements in clinical 
populations have reported mixed results. COPD patients who increased intake 
of antioxidant-rich foods had improved pulmonary function over three years 
while those on usual diets experienced continuous lung function decline.(13) 
Studies of α-tocopherol treatment in COPD patients report mainly negative 
results, although conclusions are limited by an incomplete understanding of 
potential to benefit, the short duration of studies, and case heterogeneity.(14-
16) Very few large, randomised studies of non-diseased individuals have been 
completed. In the Heart Protection Study (HPS), which included participants 
with coronary disease, other occlusive arterial disease, or diabetes, a post-hoc 
analysis found no effect of vitamin E supplements on the occurrence of 
respiratory-related death, on COPD/asthma hospitalization rates, or on 
pulmonary function measured by spirometry at the end of the study.(17) In the 
Alpha-Tocopherol and Beta-Carotene (ATBC) study, a study of male cigarette 
smokers, there was no effect of α-tocopherol on the incidence of chronic 
bronchitis or COPD symptoms.(16)  
Using data from the Women’s Health Study (WHS), a large study of 
apparently healthy women aged > 45 years, we tested the hypothesis that 
supplementation with 600 IUs of α-tocopherol every other day decreases the 
occurrence rate of chronic lung disease. 
 
Methods 
Study Design 
The WHS, a randomised, double-blind, placebo-controlled, two-by-two 
factorial trial assessed risks and benefits of vitamin E supplements (600 IU 
every other day; Natural Source Vitamin E Association, Washington, DC, 
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USA) and/or aspirin (100 mg every other day; Bayer AG, Leverkusen, 
Germany) in the primary prevention of cardiovascular disease and cancer. Full 
details of the study design are published elsewhere. The study was registered 
with clinicaltrials.gov (NCT00000479). 
Eligibility criteria included: age ≥45 years, healthcare professional, U.S. 
residence, no previous history of coronary heart disease, cerebrovascular 
disease, cancer (except non-melanoma skin cancer), or other major chronic 
illness; no more than weekly use of vitamins E, A, or β-carotene supplements; 
no history of adverse aspirin effects; less than weekly use of aspirin or non-
steroidal anti-inflammatory drug (NSAID), or willingness to forgo; no use of 
anticoagulants or corticosteroids. A 3-month placebo-only run-in period 
identified likely long-term compliers. Of these, 39,876 women remained willing 
and eligible and were randomised into WHS between April 1993 and January 
1996.(18)  
Questionnaire Data 
Mailed questionnaires collected baseline data on anthropometric, 
demographic, lifestyle, and clinical characteristics.  Follow-up questionnaires, 
completed twice during the first year and annually thereafter, assessed study 
supplement compliance, new disease occurrence and diagnosis date, 
personal characteristics and habits, non-study aspirin, vitamin and NSAID use, 
and side effects. Compliance, defined as taking two-thirds of study 
supplements, was similar (78.9% and 71.6% at 5 and 10 years, respectively) 
between active and placebo groups.(19) Non-trial vitamin E supplement use 
≥4 days/month was 10.0% and 10.9% at 5 and 10 years, respectively.(19)  
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Statistical Analysis 
1,279 women reported prevalent CLD (638 in vitamin E group; 641 in 
placebo group), thus 38,597 participants were available for analyses. All 
analyses followed the intention-to-treat principle. Cumulative incidence of CLD 
by study arm was assessed using Kaplan-Meier methods and log-rank tests to 
compare survival curves. Cox proportional hazards models estimated hazard 
ratios. Further models considered whether the effect of vitamin E on incident 
CLD was modified by smoking status, age, body mass index, multivitamin use, 
alcohol intake, baseline asthma, history of cholesterol levels ≥240mg/dl, or 
randomised aspirin assignment. Effect modification was tested for statistical 
significance using likelihood ratio tests comparing models with and without 
interaction terms. Data management and analyses were completed in SAS 
(SAS Institute Inc., Cary, NC). 
 
Results 
Baseline characteristics in the 38,597 participants, summarized in Table 
2.1, were balanced between the vitamin E and placebo arms. Thus, 
participants in both arms were similar on age, smoking, body mass index, 
multivitamin use, dietary intake of vitamin E, alcohol intake, history of asthma 
diagnosis, and percent with cholesterol ≥240 mg/dl (Table 2.1). The mean age 
of study participants was 54.5 years, and women were followed on average for 
9.8 years (376,710 person-years; 188,578 person-years in the vitamin E arm, 
188,132 person-years in the placebo arm). 
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Table 2.1  Baseline characteristics of Women’s Health Study participants by 
vitamin E randomisation 
 
 
Vitamin E 
(N=19299)* 
Placebo 
(N=19298)† 
Characteristic No. (%)‡ No. (%)‡ 
Demographic/lifestyle   
Age, years‡ 54.5 (7.0) 54.6 (7.0) 
<55 11714 (60.7) 11679 (60.5) 
55-64 5654 (29.3) 5677 (29.4) 
≥65 1931 (10.0) 1942 (10.1) 
Cigarette smoking     
Current 2434 (12.6) 2491 (12.9) 
Past 6937 (36.0) 6823 (35.4) 
Never 9909 (51.4) 9968 (51.7) 
Average duration, years‡§ 18.8 (12.5) 18.9 (12.6) 
Body mass index, kg/m2‡ 26.0 (5.0) 26.0 (5.0) 
<25.0 9598 (50.8) 9670 (51.1) 
25.0-<30.0 5880 (31.1) 5837 (30.8) 
≥30.0 3404 (18.0) 3411 (18.0) 
Nutrition   
Multivitamin Use     
Never 2521 (13.2) 2553 (13.4) 
Past only 10927 (57.4) 10982 (57.7) 
Current 5574 (29.3) 5499 (28.9) 
Vitamin E intake, mg/day     
Diet only‡ 6.6 (5.0) 6.6 (5.3) 
Diet + Supplements‡ 63.2 (143.0) 62.6 (140.9) 
Alcohol intake   
Rare/never 8743 (45.3) 8590 (44.5) 
1-3/month 2531 (13.1) 2553 (13.2) 
1-6/week 6048 (31.4) 6194 (32.1) 
1+/day 1970 (10.2) 1959 (10.2) 
Medical conditions   
Asthma diagnosis 1104 (5.7) 1105 (5.7) 
Cholesterol ≥240 mg/dl 5615 (29.1) 5688 (29.5) 
Study aspirin assignment 9638 (49.9) 9654 (50.0) 
*N total for each characteristic ranges from 18,882 to 19,299, given missing data in some 
variables 
†N total for each characteristic ranges from 18,918 to 19,298, given missing data in some 
variables 
‡Continuous variables are presented as means (SD) 
§Average smoking duration for current and past smokers only 
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Participants reported 1,606 new diagnoses of chronic lung disease, 
corresponding to a cumulative incidence of 4.2%. Participants in the vitamin E 
arm reported 760 incident CLD diagnoses (cumulative incidence, 3.9%) 
compared to 846 occurrences in the placebo arm (cumulative incidence, 
4.4%), corresponding to a statistically significant 10% reduction in risk among 
participants randomised to vitamin E supplements (hazard rate (HR) 0.90; 
95% confidence interval (CI) 0.81-0.99; p = 0.029). Comparing the cumulative 
CLD incidence by year of follow-up in the vitamin E and placebo groups (figure 
2.2) the curves separate at about 1.5 years on study and continue to diverge 
until about 5 years of supplementation, maintaining a consistent separation 
thereafter. In contrast, the aspirin intervention had little or no association with 
risk of chronic lung disease; the hazard ratio was 0.98 (95% CI 0.89-1.08). 
 
 
Figure 2.2 Cumulative incidence of chronic lung disease during the 
randomised component of the Women’s Health Study. 
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Cigarette smoking had a strong association with CLD incidence (current 
smoker vs. never smoker: HR 4.17; 95% CI 3.70-4.70; p = <0.0001). In 
addition, other known COPD risk factors were positively associated with the 
CLD outcome: older age at randomization (age ≥65 years vs. <55 years; HR 
2.38; 95% CI 2.07-2.73; p = <0.0001), obesity (BMI ≥30.0 vs. <25.0; HR 1.60; 
95% CI 1.41-1.81; p = <0.0001), asthma diagnosis prior to randomization (HR 
1.94; 95% CI 1.65-2.28; p = <0.0001), and hypercholesterolemia (HR 1.42; 
95% CI 1.28-1.57; p = <0.0001).  
There was no statistical evidence that the effect of randomised vitamin 
E assignment on CLD risk was modified by age (p=0.86), smoking status 
(p=0.96), body mass index (p=0.25), multivitamin use (p=0.67), baseline 
asthma history (p=0.89), cholesterol ≥240 mg/dl (p=0.84), or by study aspirin 
assignment (p=0.19) (figure 2.3).  Alcohol intake was borderline statistically 
significant (p=0.054) as a modifier of the effect of vitamin E on CLD, and 
women consuming one or more alcoholic drinks per day had the strongest 
vitamin E protective effect. In additional analyses, there was no evidence of 
effect modification by race, exercise frequency, hypertension, and baseline 
dietary intake of either vitamin E or C. For all models, controlling for 
randomised aspirin assignment did not alter the effect of vitamin E supplement 
assignment on CLD risk. An additional sensitivity analysis was conducted, 
censoring women who reported incident asthma from the CLD analysis; the 
association of vitamin E was similar with a 9% reduction in risk of CLD (HR 
0.91, 95% CI: 0.81-1.03). 
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Figure 2.3 Effect modification of the vitamin E/chronic lung disease effect in 
the Women’s Health Study. BMI, Body mass index. 
 
Discussion 
In this large, randomised, double-blind, placebo-controlled trial in 
apparently healthy women 600 IU of vitamin E on alternate days reduced the 
risk of self-reported newly diagnosed chronic lung disease by approximately 
10%. There was no statistically significant difference in the magnitude of the 
effect of vitamin E by age, smoking status, randomised aspirin assignment, 
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multivitamin use, or asthma history, and the protective effect was slightly 
stronger in women consuming > 1 drink/day. Randomised assignment to 
aspirin had no association with the risk of CLD. 
 Two prior randomised trials investigated vitamin E supplementation in 
relation to lung outcomes, and both reported no effect of intervention.(16;17) 
In the Heart Protection Study (HPS) 20,536 adults aged 40-80 with prevalent 
coronary artery disease (CAD) were randomised to a combined intervention of 
600 IUs of vitamin E, 250 mg vitamin C, and 20 mg β-carotene or placebo 
daily for 5 years.(17) HPS differed from the WHS in important ways. HPS 
enroled participants with clinically diagnosed CAD, occlusive arterial disease, 
or diabetes and 75% of participants were men.(17) WHS comprised women 
without cardiovascular disease history. Study duration (5 years in HPS vs. 10 
yrs in WHS) and supplement formulation (HPS, combined supplement vs. 
WHS, vitamin E alone) also differed. Finally, the outcomes in HPS, pulmonary 
function measured by spirometry, death due to respiratory illness, and COPD 
or asthma-related hospitalizations differed from the WHS, which investigated 
incidence of chronic lung disease diagnosis.(17)  
 In the Alpha-tocopherol Beta-carotene Cancer Prevention Study 
(ATBC) 29,133 male cigarette smokers aged 50-69 were randomised to 
receive 50 mg vitamin E and/or 20 mg β-carotene or placebo daily for 4 
years.(16) ATBC differed substantially from the WHS in the supplement 
studied, the trial duration and the population studied.(16) ATBC reported no 
effect of vitamin E on COPD-related symptoms, a substantially different 
endpoint than incidence of chronic lung disease diagnosis.  
 Strengths of the WHS include the large number of participants, the 
large number of self-reported, MD-diagnosed CLD outcomes, high adherence 
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rate, and high follow-up rate. CLD is associated with ageing, thus the minimum 
age required for study enrolment, 45 years, yielded a population at risk for 
incident CLD risk. 
Several limitations deserve mention. While the size of this trial was 
adequate to detect a statistically significant small to moderate effect of vitamin 
E supplementation on incident CLD, the trial was not specifically designed to 
test the studied hypothesis. Thus, outcome ascertainment was based solely 
on self-reported MD-diagnosis, a concern that is partly mitigated by the fact 
that participants were female health professionals. A validation study of self-
reported COPD outcomes in female nurses found that 78% of self-reported 
COPD cases were confirmed with medical record review, suggesting self-
report of lung disease by the female health professionals comprising the WHS 
is likely to have excellent validity.(20) While the question about outcome 
occurrence listed bronchiectasis, the low incidence of bronchiectasis in this 
age range leads to the reasonable assumption that most occurrences reported 
refer to COPD.  Current cigarette smoking was a strong predictor of CLD in 
these data, providing evidence of face validity for the outcome ascertainment. 
Finally, if the outcome is misclassified (either by undercounting cases or by 
including false positives) the misclassification is likely to affect both arms of 
the trial equally, and the hazard ratio may therefore be an underestimate of the 
true effect size.  
Outcome Definition 
The complexity of airway disease phenotypes raises substantial 
concern about misdiagnosis of COPD and asthma, particularly in women.(21) 
To address the possibility that women reporting a new asthma diagnosis 
actually had COPD, a sensitivity analysis was conducted. When women 
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reporting incident asthma were excluded from the analysis, vitamin E was 
associated with a 9% reduction in the risk of CLD (HR 0.91, 95% CI: 0.81-
1.03), similar to the findings in the full study group. There was little or no effect 
of vitamin E supplementation on incident self-reported MD-diagnosed asthma 
(HR 0.99; 95% CI 0.90-1.08; p=0.83). Kurth et al (2008) investigated the effect 
of randomized aspirin assignment on the risk of incident adult-onset asthma in 
the Women’s Health Study; women in the aspirin arm had a 10% lower risk of 
incident asthma compared to women in the placebo arm.(22) When women 
developing chronic obstructive pulmonary disease over follow-up were 
censored from the analysis, the findings were similar. The effect of aspirin on 
incident asthma, and the lack of effect of aspirin on incident CLD supports the 
notion of differentiation in the self-reported diagnoses.(22)  
Proposed Mechanisms 
 Prior studies document the presence of vitamin E in the lung 
compartment and the mechanisms of delivery of vitamin E to alveolar type II 
cells in the lung.(23) Vitamin E transport to the type II cells is hypothesised to 
occur via high-density lipoproteins because type II cells have no physical 
contact with plasma and interact only with interstitial fluid lipoproteins, which 
are predominantly HDL lipoproteins.(23) Thus, the concentration of HDL 
cholesterol in the plasma and in the interstitial fluid predicts the amount of 
vitamin E available to the lung compartment to combat oxidative stress. Prior 
studies have reported that HDL cholesterol and apolipoprotein A-I levels are 
positively associated with FEV1, even after adjusting for serum antioxidant 
concentrations, a finding that may reflect the delivery of vitamin E to lung 
tissues.(24) Thus, a higher HDL cholesterol level is hypothesised to deliver a 
greater effective dose of vitamin E to the lung compartment. 
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 Given that HDL cholesterol levels are 20-25% higher in women 
compared to men in all age groups, differences in the biologically effective 
dose of vitamin E may contribute to the difference in findings between women 
in WHS and the predominantly male participants in the HPS and ATBC.(25) 
Sex-related differences in the effect of vitamin E supplementation on all-cause 
mortality have been reported, with stronger protective effects of low-dose 
vitamin E supplementation evident in study populations comprised of ≥75% 
women.(26)  
 Alcohol intake is proposed to reduce CVD risk by raising HDL 
cholesterol levels, and a threshold of > 1 drink per day is associated with both 
higher HDL cholesterol levels and attenuation in CVD risk.(27;28) Given the 
important role of HDL cholesterol in transporting vitamin E to the lung, 
exploratory analyses considered alcohol intake as a modifier of the effect of 
vitamin E on CLD. Among variables considered as possible effect modifiers, 
alcohol intake was marginally statistically significant (p=0.054), and the 
preventive effect of vitamin E on CLD was greatest in women consuming the 
highest level of alcohol (> 1 drink/day). These preliminary findings are 
consistent with the hypothesis that delivery of vitamin E to lung tissue may 
vary by plasma levels of HDL cholesterol. 
 Under our hypothesis, the effect of antioxidant supplementation was 
expected to be stronger in participants with a higher oxidative burden, for 
example, in current cigarette smokers. Contrary to expectation, there was no 
evidence of effect modification by smoking. If supplementation with vitamin E 
acts through other systemic mechanisms, for example by improving immune 
system function, then a general effect of vitamin E would be supported.(29) 
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Efficacy and Safety Considerations 
 There has been substantial discussion of the efficacy and safety of 
vitamin E supplementation in the scientific literature.(30) Potential harmful 
effects include an increased risk of all cause mortality, susceptibility to 
bleeding, and haemorrhagic stroke.(31-33) The meta-analysis linking high-
dose vitamin E supplementation to increased risk of mortality, however, has 
been criticised for its methodology and a recent paper suggested that vitamin 
E has beneficial effects on ischemic stroke risk.(33-35) Thus, the design of 
future vitamin E supplementation trials must carefully consider information 
about risks and benefits, and recommendations may need to be tailored to 
specific populations. 
Summary and Conclusion 
The WHS was comprised of female health professionals aged > 45, the 
majority of whom were of European descent. Healthy women taking 600 IU 
vitamin E supplements every other day were 10% less likely to report a new 
chronic lung disease diagnosis during the study period. Any decisions about 
use of vitamin E as a preventive must consider information about vitamin E 
associated risks and bioavailability.(26;30;31;34;35) Given that there are few 
prevention strategies for emphysema and chronic bronchitis, further study of 
vitamin E in relation to chronic obstructive pulmonary disease is of public 
health interest.   
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CHAPTER 3 
EFFECT OF SUPPLEMENTARY NUTRIENTS WITH 
 ANTIOXIDANT PROPERTIES ON PLASMA AND  
AIRWAY LINING FLUID IN CIGARETTE SMOKERS 
   
 
Abstract 
Background: Consequent to the oxidant stress imposed by smoking, the 
human airway epithelium marshals both endogenous and exogenous 
antioxidant defenses. When these defenses are breeched oxidative stress 
causes cellular damage, contributing significantly to lung tissue damage and 
the development of COPD. Prior epidemiologic studies demonstrate a direct 
association between serum markers of nutrients with antioxidant properties 
and lung outcomes, but no studies have investigated the degree to which 
supplementation affects nutrient levels in the lung compartment. We 
hypothesized that oral supplementation with nutrients would alter the lung 
compartment levels of the nutrients and lower a systemic marker of oxidative 
stress.  
Methods: A placebo controlled, double-blinded study was conducted to 
assess the effect of 1 month of daily supplementation with vitamin E (400 IU), 
vitamin C (1000 mg) and selenium (400 µg), or matched placebo, on plasma 
and bronchioalveolar lavage fluid (BALF) nutrient levels in active healthy 
smokers. Participants (n=24) were randomized 2:1 (vitamin: placebo), and 
plasma and BALF were obtained at baseline and 1 month post-
supplementation. Nutrients and a marker of oxidative stress were assayed in 
plasma and BALF via GC/MS, ICP-MS and ELISA methods. 
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Results: Supplementation increased plasma levels of all nutrients (p<0.002, 
all comparisons pre vs post) in participants in the intervention group; levels 
were unchanged in participants on placebo (all p>0.172), with the exception of 
selenium, which declined slightly (p=0.01). Vitamin E and selenium were 
assayed in BALF, and both nutrients increased with supplementation for the 
intervention group only (p<0.02, for changes in intervention group). F2-
isoprostanes, an oxidative stress biomarker, were not significantly reduced by 
the antioxidant intervention.  
Conclusions: Vitamin supplementation increased lung levels of both vitamin 
E and selenium, thus confirming the delivery of these nutrients to target tissue. 
While supplementation had no overall effect on a systemic biological marker of 
oxidative stress, only two participants had pre-supplementation evidence of 
high oxidative stress. Thus there was limited opportunity to show changes in 
oxidative stress levels in this study. 
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Introduction 
 Chronic obstructive pulmonary disease (COPD), is characterized by 
airflow limitation that is not fully reversible.(1) The disease progresses 
insidiously, and by the time the patient becomes symptomatic and the COPD 
diagnosis is made, lung damage is usually significant.(2-4) COPD comprises a 
significant health burden, and is predicted to become the 3rd leading cause of 
death worldwide by 2020.(1;5) Cigarette smoking is the most important risk 
factor for the development of COPD, with current or former smokers 
comprising about 90% of patients who develop the disease.(6) Smoking 
presents a huge oxidant burden to the airways, and each puff of cigarette 
smoke contains 1014 free radicals.(7) When the antioxidant defenses of the 
airways are overwhelmed, oxidative stress causes cellular damage, 
contributing significantly to lung tissue damage and the development of 
COPD.(8;9)  
 Whereas the lung airway epithelium and the airway epithelial lining fluid 
have endogenous antioxidant defenses, exogenous antioxidants in the diet 
also contribute to protecting the lung epithelium from oxidant stress.(10-13) 
Key nutrients with antioxidant properties include vitamin E, vitamin C and 
selenium. Lower intake of nutrients and lower serum nutrient levels are 
associated with lower lung function in both smokers and nonsmokers.(14-20) 
A seminel study of participants in the Third National Health and Nutrition 
Examination Survey (NHANES III) found that higher dietary intake of vitamins 
E and C and serum levels of vitamins E and C, and selenium were positively 
associated with lung function assessed by spirometry.(21) The joint effect of 
dietary antioxidant intake was higher than the effect when nutrients were 
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considered individually, suggesting a synergistic relation among antioxidants 
in the protection of the lung.(21)  
 Studies comparing COPD patients to healthy individuals report lower 
plasma and peripheral skeletal muscle vitamin E ( -tocopherol) concentrations 
in patients, and a lower risk of death from respiratory disease with higher 
serum -tocopherol concentration, but whether nutrition contributes to the 
onset of COPD is less clear.(15;22;23)  
 In light of past findings, supplementation of the antioxidant defenses of 
the lung with exogenous nutrients with antioxidant properties is a logical 
intervention strategy that is hypothesized to protect the lung from the oxidant 
stress of smoking. To test this hypothesis, a placebo controlled, double-
blinded study was conducted to assess the effect of 1 month of 
supplementation (daily vitamin C, vitamin E and selenium) or placebo on 
plasma and bronchioalveolar lavage fluid (BALF) levels of nutrients in active 
healthy smokers. The study investigated the following hypotheses: (1) 
supplementation with nutrients raises not only plasma nutrient levels, but also 
nutrient levels in the lung epithelial lining fluid as assessed by BALF; and (2) 
increasing antioxidant capacity through exogenous sources reduces a 
systemic marker of oxidative stress, signaling a potential mechanism through 
which nutrients act directly in the lung compartment.  
 
Methods 
Study Design 
 Healthy smokers were recruited from the general population through 
advertisements in the press and on the world-wide web. Participants were 
evaluated at the Weill Cornell NIH General Clinical Research Center and 
35 
 
Department of Genetic Medicine clinical research facility under protocols 
approved by the Weill Cornell Medical College Institutional Review Board. All 
subjects were current smokers by history, with active smoking confirmed by 
urine metabolites and venous carboxyhemoglobin. Participants were 
determined to be phenotypically normal on the basis of history, physical 
examination, routine blood screening tests, urinalysis, chest imaging, 
electrocardiogram, and pulmonary function testing. All individuals were HIV-
negative and had normal alpha1-antitrypsin levels. Inclusion criteria included: 
good health with no history of chronic lung disease, including asthma and 
without recurrent or recent acute pulmonary disease, not pregnant, willingness 
to participate in the study and ability to provide informed consent, no use of 
antioxidant dietary supplements in the prior 3 months, no allergies to 
medications used in the brochoscopy procedure. Exclusion criteria included: 
inability to meet inclusion criteria, current active infection or acute illness of 
any kind, alcohol or drug abuse within the past 6 months, and evidence of 
malignancy within the past 5 years. Individuals meeting inclusion/exclusion 
criteria underwent assessment at baseline for the smoking and clinical 
variables listed above.  
 Participants were randomized 2:1 to receive either nutrient supplements 
(daily vitamin C 1000 mg, vitamin E 400 IU and selenium 400 µg) or matched 
placebos for one month. All participants were evaluated at study baseline and 
1 month after supplementation; evaluations included a blood draw, pulmonary 
function test, questionnaires, and bronchoscopy to sample lung epithelial lining 
fluid and the airway epithelium. Compliance was encouraged with a mid-study 
telephone call and participants were asked to bring their empty pill cases to 
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the second clinic visit so that unused supplements could be counted and 
recorded. 
Dietary Nutrient Intake Assessment 
 At randomization participants completed a 12-page food frequency 
questionnaire (FFQ) to assess usual dietary intake. The FFQ was developed 
by the Nutrition Assessment Shared Resource (NASR) of the Fred Hutchinson 
Cancer Research Center (FHCRC). The FFQ included questions on 103 foods 
and 17 beverages, plus 12 questions on food preparation and 2 questions on 
fruit and vegetables consumption patterns. The dietary intake of more than 
130 nutrients was determined using the Nutrient Data System for Research 
(NDSR), developed by the Nutrition Coordinating Center, University of 
Minnesota, Minneapolis, MN, Food and Nutrient Database (2009 versions of 
software and database). 
Supplements 
 Vitamin C supplements were provided by NOW Foods (Bloomingdale, 
IL) and contained ascorbic acid in a formulation with cellulose, croscarmellose 
sodium, stearic acid and magnesium stearate; matched placebo contained 
additional cellulose in place of ascorbic acid, but was otherwise identical. In 
two batches of ascorbic acid supplements the manufacturer‘s reported 
contents of active ingredient were 1094.1 mg/tablet and 1122.5 mg/tablet.  
 Vitamin E supplements were provided by Roche Vitamins (Nutley, NJ) 
and contained all-rac- -tocopherol suspended in vegetable oil; matched 
placebos contained only vegetable oil. Roche Vitamins did not provide 
detailed certificates of analysis for the supplements.  
 Selenium supplements were provided by Sabinsa, Inc. (Piscataway, 
NJ) and contained L-selenomethionine and white powder filler; matched 
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placebos contained only the white powder filler. Sabinsa, Inc. provided 
certificates of analysis of the supplement content and dose. Average content 
of the selenomethionine supplements was 215.0 g per capsule.  
 The vitamin E and selenium supplements were initially supplied through 
the pharmacy of The Selenium and Vitamin E Cancer Prevention Trial 
(SELECT) and then sourced directly though the suppliers. Vitamin E and 
vitamin C supplements were independently analyzed for content and dosage 
by Craft Technologies, Inc. (Wilson, NC). Vitamin C supplements from two lots 
were analyzed and average ascorbic acid contents were 1160 mg/tablet and 
1142 mg/tablet, respectively. Vitamin E supplements from two lots contained 
547 IU/softgel and 521 IU/softgel, respectively. All supplements and placebo 
were provided free of charge. Supplements were packaged into 30-day pill 
cases by the Human Metabolic Research Unit, Cornell University, and labeled 
for use by the clinical center. 
Biologic Specimen Collection 
 At baseline and one month after active supplementation or placebo, 
specimens of plasma, urine, large airway epithelium and lung epithelial lining 
fluid (BALF) were collected. 
 For plasma levels of nutrients, 50 ml of blood was collected in 
heparinized tubes (BD Vacutainers, NJ), centrifuged at 1000 g for 30 min at 
4°C, aliquoted into cryovials and frozen at -80°C for subsequent analysis. To 
preserve vitamin C, a 0.7 ml aliquot was added to a cryogenic vial containing 
0.7 ml of pre-cooled 10% meta-phosphoric acid solution then immediately 
frozen at -80°C.  
 Lung BALF was collected by bronchoalveolar lavage, using 5 x 30 ml 
aliquots into the segmental bronchus of the right middle lobe.(24) The 
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bronchoalveolar lavage fluid (BALF) recovered was filtered through gauze to 
remove debris and mucus and then centrifuged at 1,200 rpm for 5 min at 4°C. 
The supernatant was separated into multiple aliquots and stored at -80°C. The 
absolute amount of BALF collected was assumed to be approximately the 
same on repeated bronchoscopies in the same participant, and thus correction 
for dilution was not applied.(25-27)  
Nutrient Assay Methods 
Supplemental methods are in the Appendix, Supplemental Methods A.1. 
Vitamin C  
Ascorbic acid concentration in plasma samples was determined by 
HPLC. Briefly, 50 l of supernatant was mixed with a reducing reagent then 
incubated. Samples were then acidified and an internal standard was added. 
Analysis by HPLC with UV detection at 245 nm was conducted. Three known-
value serum standards (0.41 g/ml ± 11.1%, 1.94 g/ml ± 2.66%, and 14.1 
g/ml ± 1.63%) were concurrently measured in duplicate to assess assay 
accuracy. Precision was assessed by determining the average coefficient of 
variation, across all assay runs, which was 5.14% for the six measurements of 
the three standards. Vitamin C measurements were completed by Craft 
Technologies (Wilson, NC).   
In a recent study, vitamin C supplementation increased ascorbic acid 
concentrations in nasal lavage fluid for only a few hours post-supplementation, 
and levels returned to pre-supplementation values within 24 hours of last 
supplement use.(12;28) Given that the current study did not control the timing 
of supplementation relative to BALF collection, vitamin C was not assessed in 
BALF.  
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Vitamin E  
Alpha-tocopherol concentration in plasma and BALF samples was 
determined by GC-MS. Briefly, for each sample a 9- -tocopherol internal 
standard was added then lipids were extracted with organic solvents and the 
upper layer was transferred to a vial. The samples were evaporated to dryness 
under a nitrogen stream in a water bath and the resulting residues were 
silylated in pyridine with N,O-bis[trimethylsilyl]trifluoroacetimide (Thermo 
Scientific, Rockford, IL). The vials were tightly capped with nitrogen filling the 
headspace and placed in a 75ºC dry oven for 25 minutes. For determination of 
-tocopherol in the high density lipoprotein (HDL) fraction of the plasma, HDL 
was separated from the plasma using an HDL cholesterol precipitating reagent 
(Stanbio, Boerne, TX) prior to the standard sample preparation. -Tocopherol 
concentrations in plasma, HDL, and bronchioalveolar lavage fluid samples 
were determined by GC-MS, using a Hewlett Packard 6890 gas 
chromatograph coupled to a Hewlett Packard 6890 mass spectrometer. 
Samples were assayed in duplicate and average coefficients of variation were 
determined for total -tocopherol and for cholesterol-adjusted total -
tocopherol (where cholesterol was measured with the GC-MS method), 
respectively, with values as follows: plasma total -tocopherol CVs were 4.2% 
and 2.4%, for total and cholesterol-adjusted, respectively; HDL -tocopherol 
CVs were13.2% and 4.0%, for total and cholesterol-adjusted, respectively; 
bronchioalveloar lavage fluid -tocopherol CVs were 11.6% and 6.2% for total 
and cholesterol-adjusted, respectively. Vitamin E assays were completed in 
the Division of Nutritional Sciences, Cornell University, Ithaca, NY. 
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Selenium  
  Plasma samples and four reference standards were diluted 20-fold with 
2% HNO3. An Agilent 7500 cs/ce quadrupole ICP-MS equipped with a collision 
reaction cell was used to determine total selenium concentration in plasma 
samples. The ion intensity at m/z 78 was used to monitor Se and 89Y was 
used as an internal standard for plasma samples. Plasma sample data were 
collected using the Spectrum mode for direct analysis. Two reference standard 
solutions, 1 ppb and 5 ppb, were run at regular intervals throughout sample 
testing and average concentrations were determined to be 1.002 ppb and 
5.117 ppb, respectively with standard deviations of 0.023 and 0.073. All four 
reference materials were determined to have values within the range of 
acceptable results for the material. 
BALF samples were evaporated and reconstituted in 2% HNO3 spiked 
with 1ppb Ge to achieve a 5-fold concentration of the original solution. The ion 
intensity at m/z 78 was used to monitor Se and 72Ge was used as an internal 
standard for BALF samples. BALF sample data was collected using the 
transient mode and data were individually calculated for each assay. A 
reference solution containing 1 ppb of Ge and Se in 2% HNO3 was analyzed 
at regular intervals throughout sample testing. The BALF was primarily saline 
solution (i.e., highly dilute BALF) and the sodium contained within the BALF 
samples interfered with detector response to Ge and Se ions. Interference was 
quantitated and adjusted by assessing Ge and Se response in the reference 
solution and comparing it to the reduced response in the samples that were 
reconstituted in the Ge-spiked solution. Selenium assays were performed by 
the USDA Plant, Soil, and Nutrition Laboratory, Cornell University, Ithaca, NY. 
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F2-isoprostane Assay Methods 
Plasma F2-Isoprostanes(29;30)
 
Briefly, to a 1-3 ml plasma aliquot 1.0 ng of [2H4]-15-F2t-IsoP ([
2H4]-8-
iso-PGF2a (Cayman Chemical, Ann Arbor, MI) was added, serving as an 
internal standard.  The sample was purified using Sep-Pak cartridges and the 
eluate was collected, dried down and converted to the pentafluorobenzyl 
(PFB) esters by the addition of 40 μl of a 10% solution of pentafluorobenzyl 
bromide in acetonitrile and 20 μl of a solution of 10% diisopropylethanolamine 
in acetonitrile, incubated, then dried under nitrogen. The residue was 
reconstituted in 30 μl chloroform and 20 μl methanol and the PFB esters and 
methyl ester of PGF2α were purified in separate lanes by thin layer 
chromatography.  Compounds migrating in the region 1 cm below the PGF2α 
standard to 1.0 cm above the standard are scraped from the TLC plate, 
extracted with 1 ml ethyl acetate, and dried under nitrogen.  The resulting 
compounds are converted to trimethylsilyl (TMS) ether derivatives by addition 
of 20 μl N,O-bis(trimethylsilyl)trifluoroacetamide and 10 μl dimethylformamide,  
incubated then dried under nitrogen.  The residue was re-dissolved for GC/MS 
analysis in 20 μl undecane. 
Gas chromatography-negative-ion chemical ionization mass 
spectrometry (GC/NICI-MS) was carried out on an Agilent 5973 Inert Mass 
Selective Detector coupled with an Agilent 6890n Network GC system (Agilent 
Labs, Torrance, CA) interfaced with an Agilent computer. The lower limit of 
detection of F2-IsoPs is in the range of 4 pg using an internal standard with a 
blank of 3 parts per thousand.  The precision of this assay in biological fluids is 
+6% and the accuracy 94%. Plasma F2-isoprostane measurements were 
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performed by the Eicosanoid Core Laboratory, Vanderbilt University Medical 
Center, Nashville, TN. 
Urine F2-isoprostanes 
Urine was collected using a ―clean catch‖ method into sterile urine 
collection containers. Urine samples were pipetted into cryovials in 2 ml 
aliquots then immediately frozen at -80oC. Thawed samples were centrifuged 
to remove particulates, then 1 ml aliquots were added to microcentrifuge 
tubes. Repeated sorbent washing procedures achieved initial purification of 
the specimens and the washed sorbent was then re-suspended in 0.5 ml 95% 
ethanol (elution buffer) (Fisher Scientific, Pittsburgh, PA) and briefly vortexed. 
The sample was then centrifuged and the elution buffer was removed and 
saved. The re-suspension was repeated and the elution buffer washes were 
all combined and dried down overnight on a speed vacuum. Dried samples 
were then dissolved in 1 ml of EIA buffer (Cayman Chemicals, Ann Arbor, MI). 
 F2-isoprostanes in urine samples and 8 standard samples prepared by 
serial dilution were measured using a competitive enzyme linked 
immunoassay (ELISA) kit from Cayman Chemicals (Ann Arbor, MI). The tracer 
and antiserum were each reconstituted with 6 ml of EIA buffer. The standard 
protocol for plate set up and development provided by Cayman Chemicals 
was used. The plate was read by spectrophotometry at 405 nm wavelength 
after 60 minutes and 90 minutes of development. 
Control samples were run on each plate and the overall coefficient of 
variation was 18.7%. Additionally, standard curve correlation values were 
calculated at two time points and the average R2 value was 0.9911 at each 
time point with average R2 standard deviation of 0.0040. 
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Urine Creatinine 
Creatinine in urine samples was measured on a Siemens Dimension 
Xpand Plus using standard methods recommended by the manufacturer. 
Plasma Cholesterols and Triglycerides Assay Methods 
Total, HDL, and low density lipoprotein (LDL) cholesterol and 
triglycerides were determined using chemiluminescence under standard 
methods on a Siemens Dimension Xpand, a Centers for Disease Control and 
Prevention certified instrument. Average within-run and between-run 
coefficients of variation for the analytes were as follows: total cholesterol, 
0.71% and 1.94%; HDL cholesterol, 0.36% and 4.20%; LDL cholesterol, 
0.48% and 3.10%; and triglycerides, 0.28% and 2.12%. Two control samples, 
Biorad Liquid Assayed Multiqual Level 1 and Level 3, were assayed and all 
values for the lipids were determined to be within the acceptable range. 
Urine F2-isoprostanes, urine creatinine, and plasma cholesterol and 
triglyceride assays were conducted in the Human Metabolic Research Unit, 
Cornell University, Ithaca, NY. 
Data Analysis 
All analyses were carried out in SAS 9.2 (Cary, NC).  Univariate 
methods were used to inspect all data, and to make comparisons to known 
ranges.  The pre-post association of nutrients was assessed with a paired t-
test—given non-independence of the samples—for plasma and BALF 
nutrients and oxidative stress markers. All data were plotted for visual 
inspection of trends. Next, the association of change in plasma compartment 
with change in lung compartment was assessed with the Pearson product 
moment correlation coefficient, separately by treatment group, and the 
magnitude of the effect and variance explained was estimated with ordinary 
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least squares linear regression. In regression models of change in BALF 
nutrient predicted by change in plasma nutrient, effect modification was tested 
by adding product terms to the model. For example, to assess whether the 
association of BALF changes with plasma changes in each nutrient differed by 
gender, the gender by plasma change product term was added to the model.  
 
Results 
Participant Characteristics 
 A total of 26 healthy smokers were included in the study; 16 participants 
received the ‗active‘ intervention, which was a combination of vitamin E, 
selenium and vitamin C (active intervention group) and 8 participants received 
matched placebos (placebo group). Principal component analysis of the 
plasma nutrient levels for all participants‘ revealed two non-compliant 
participants in the active group; all plasma nutrient values for these 
participants at the post-supplementation time point were in the placebo range, 
thus they were excluded from further consideration and all remaining analyses 
are based on 24 participants (Appendix Figure A.1).  
 All participants had normal general physical examinations and no 
significant prior medical history. Smoking status was confirmed by urine 
nicotine and cotinine levels. There were no differences between the active and 
placebo group with regard to gender, ethnicity, pack-year history, urine 
nicotine and cotinine, venous blood carboxyhemoglobin levels, and pulmonary 
function tests (p>0.05 for all comparisons, Table 3.1).  
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Table 3.1 Demographics of the study population and descriptive 
characteristics of biologic measurements 
 
Variable* Placebo (N=8) Active (N=16) 
Demographic characteristics 
    Sex (male; female) 8; 0 13; 3 
    Age (years) 42.4 (11.2) 43.5 (6.9) 
    Race (B: W; O)
†
 3; 4; 1 10; 2; 4 
Smoking characteristics 
    Smoking history (pack-yr) 31.2 (12.9) 31.1 (16.5) 
    Urine nicotine (ng/ml)   
        Baseline 1760 (3082) 2041 (1636) 
        Post-intervention 1493 (681) 2239 (1703) 
    Urine cotinine (ng/ml)   
        Baseline 1421 (1263) 2095 (1295) 
        Post-intervention 1179 (481) 2007 (1221) 
Pulmonary function
‡
 
    FVC (% predicted) 107 (13) 110 (13) 
    FEV1 (% predicted) 107 (14) 104 (14) 
    FEV1/FVC (%) 82 (6) 77 (6) 
    TLC (% predicted) 100 (14) 102 (13) 
    DLCO (% predicted) 99 (14) 94 (13) 
Dietary nutrient intake
§
 
    Alpha-tocopherol (mg/day) 13.3 (7.5) 17.9 (12.9) 
    Vitamin C (mg/day) 125.3 (161.0) 192.9 (174.2) 
    Selenium ( g/day) 168.4 (51.5) 210.8 (129.4) 
* mean (standard deviation) unless otherwise indicated 
†
 B = black, W = white, O = other 
‡
 FVC - forced vital capacity, FEV1 - forced expiratory volume in first second of exhalation, 
TLC - total lung capacity, DLCO - diffusing capacity 
§
  Dietary nutrient intakes estimated from Food Frequency Questionnaire; placebo n=7, active 
n=14 
 
Response to Intervention with Antioxidant Supplements 
 In the main analysis, the mean nutrient levels pre- and post-intervention 
were assessed, as well as the mean of within-individual change, for both the 
active and placebo groups (Table 3.2). For participants in the active 
intervention arm of the study the increases in plasma nutrient levels were 
statistically significantly for all three nutrients over the 30-day intervention. 
Plasma -tocopherol increased 69.4% (p < 0.0001, for paired t-test comparing 
concentration at t0 to concentration at t1). Plasma selenium increased 78.0% 
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Table 3.2 Concentrations of supplemented nutrients and oxidant stress biological marker at baseline of study (t0) and at 1 
month post-supplementation (t1) for 24 participants in intervention study 
 
Nutrients and Metabolites 
Placebo (N=8) Active (N=16) 
t0* t1* Change**  
(%) 
P value t0* t1* Change**  
(%) 
P value 
Vitamin E 
   Plasma total -toc 
(cholesterol adjusted); mol 
-toc/mmol cholesterol 
12.1 (3.4) 13.6 (1.2) 1.5 (21.3) 0.3094 13.1 (3.3) 21.6 (6.9) 8.6 (69.4) <0.0001 
   HDL -toc; mol -
toc/mmol cholesterol in HDL  
11.8 (2.7) 13.3 (4.3) 1.5 (12.0) 0.1722 12.7 (3.4) 20.5 (6.2) 7.8 (67.1) <0.0001 
   Lung BAL -toc
†
; nmol -
toc/L 
24.2 (12.8) 19.5 (4.8) -4.7 (-5.8) 0.2648 23.9 (10.6) 36.1 (21.3) 12.2 
(64.6) 
0.0173 
Selenium 
   Plasma total selenium; g 
Se/L plasma 
197.3 (7.3) 188.6 (7.6) -8.8 (-4.4) 0.0101 193.3 (33.7) 337.9 (65.9) 144.6 
(78.0) 
<0.0001 
   Lung BAL selenium; g 
Se/L 
0.47 (0.12) 0.49 (0.10) 0.02 (5.1) 0.1613 0.41 (0.10) 0.57 (0.13) 0.16 
(46.8) 
0.0001 
Vitamin C 
   Plasma ascorbic acid; 
g/ml 
6.5 (5.7) 7.7 (5.1) 1.2 (116.1) 0.5701 8.4 (3.7) 13.5 (4.5) 5.0 
(107.3) 
0.0016 
F2-isoprostanes 
   Plasma F2-isoprostanes
‡
; 
pg/ml 
0.069 (0.026) 0.057 (0.025) -0.006 (-5.48) 0.7358 0.066 (0.05) 0.045 (0.02) -0.018  
(-17.4) 
0.0876 
Urine F2-isoprostanes
§
; 
pg/mg creatinine 
352.2 (254.8) 324.3 (148.7) 2.43 (22.83) 0.9683 365.8 
(168.6) 
338.9 
(109.7) 
-54.33  
(-3.7) 
0.2099 
*Mean (SD) 
**average of within-individual change 
†
7 in placebo group 
‡ 
15 in active
  
§
6 in placebo, 14 in active 
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(p < 0.0001) and plasma vitamin C increased 107.3% (p = 0.0016). HDL -  
tocopherol increased 67.1% (p < 0.0001). In contrast, in the placebo arm, 
plasma -tocopherol increased by 21.3% and plasma selenium declined by 
4.4%. Although the slight decrease in selenium was statistically significant (p = 
0.01) it was in the opposite direction to the supplemented group; measurement 
precision was excellent in the selenium assays, contributing to this small 
magnitude of change reaching thresholds of statistical significance. In the 
placebo group, plasma vitamin C increased by 116.1%, but this result was not 
statistically significant (p = 0.57) and was entirely driven by one person whose 
plasma vitamin C levels increased dramatically over the 30 days. When the 
outlier was omitted from the analysis, plasma vitamin C increased an average 
of 5.3% for all other placebo arm study participants (p = 0.35).  
 In the intervention arm of the study, lung vitamin E and selenium levels 
increased over the 30-day period of supplementation. -Tocopherol in BALF 
increased 64.6% (p = 0.0173) and selenium increased 78.0% (p < 0.0001). In 
contrast, there was little or no change in lung nutrient levels in the placebo 
arm: BALF -tocopherol decreased 5.8% (p = 0.2648) and selenium increased 
5.1% (p = 0.1613). 
 Plasma F2-isoprostanes were assayed as a biological marker of 
oxidative stress, and assays were completed in both plasma and urine 
samples from study participants. In the active intervention arm of the trial, over 
the 30-day period of supplementation, plasma F2-isoprostane levels 
decreased 17.4%, and the decrease was borderline statistically signficant (p = 
0.0876) and urinary F2-isoprostanes declined 3.7% (p=0.2099). Although 
neither change reached the threshold for statistical significance, the plasma 
result supports the hypothesis that supplementation reduces systemic markers 
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of oxidative stress. In the placebo arm of the study plasma F2-isoprostanes 
declined 5.48% while urinary F2-isoprostanes increased 22.83%, though 
neither result was statistically significant (p = 0.7358 and p = 0.9683, 
respectively). 
 To examine the consistency of the average change, individual 
participant data were plotted for plasma total vitamin E, HDL vitamin E, plasma 
selenium and plasma vitamin C (Figures 3.1 to 3.4). For all nutrients measured 
in plasma the active intervention group showed substantial increases in 
nutrient levels after supplementation, though individual variability is apparent, 
particularly for -tocopherol. In the placebo group slight variations in 
concentrations can be seen at the two time points, particularly for -tocopherol 
and ascorbic acid, with selenium showing the least variability over time. One 
participant on placebo had a sharp increase in plasma ascorbic acid 
concentration over the 30 day supplementation period, contrary to expectation 
given the participant was assigned to the placebo arm. Indeed, the pattern of 
change is similar to changes in participants in the active arm, raising the 
possibility of non-compliance in this participant.  
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Figure 3.1 Change in plasma -tocopherol (adjusted for total plasma 
cholesterol) from baseline to one month for individual study participants. 
 
 
 
 
Figure 3.2 Change in high density lipoprotein fraction (HDL) -tocopherol  
(adjusted for cholesterol in HDL fraction) from baseline 
 to one month for individual study participants. 
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Figure 3.3 Change in plasma selenium from baseline to one month for 
individual study participants. 
 
 
Figure 3.4 Change in plasma ascorbic acid from baseline to one month for 
individual study participants. 
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 To assess the relation of change in nutrient in the plasma compartment 
with change in nutrient in the lung compartment (BALF), the pre-post change 
in nutrients in the BALF was assessed (Figures 3.5 and 3.6). Lung -
tocopherol concentrations increased during the 30-day intervention in most 
participants in the active supplement arm of the trial and a few participants had 
marked increases in concentration. In the placebo arm of the trial there was 
little or no change in -tocopherol concentrations in the lung over the 30 day 
supplementation period. 
 
 
Figure 3.5 Change in BALF -tocopherol from baseline to one month for 
individual study participants. 
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Figure 3.6 Change in BALF selenium from baseline to one month for individual 
study participants. 
 
 The correlation between the change in plasma and the change in BALF 
nutrients was estimated (Figures 3.7, 3.8, and 3.9). Changes in cholesterol-
adjusted total plasma -tocopherol ( mol -tocopherol/mmol cholesterol) and 
BALF -tocopherol (nmol -tocopherol/L BALF) were moderately correlated, 
but the correlation was not statistically significant (p = 0.1487; Figure 3.7). 
Plasma HDL -tocopherol ( mol -tocopherol/mmol HDL cholesterol) and 
BALF -tocopherol (nmol -tocopherol/L BALF) were strongly and statistically 
significantly correlated (p = 0.0024; Figure 3.8). Plasma ( g Se/L plasma) and 
BALF ( g Se/L BALF) selenium were also strongly and significantly correlated 
(p = 0.0057; Figure 3.9). Further consideration of non-parametric models, for 
example the Spearman rank-order correlation, did not substantially alter these 
findings. 
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Figure 3.7 Correlation of changes in plasma -tocopherol  
(adjusted for total plasma cholesterol) and BALF -tocopherol 
 concentrations (where change = -toc1 month – -tocbaseline). 
 
  
Figure 3.8 Correlation of changes in high density lipoprotein fraction  
(HDL) -tocopherol and BALF -tocopherol concentrations  
(where change = -toc1 month – -tocbaseline). 
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Figure 3.9 Correlation of changes in plasma selenium and BALF selenium 
concentrations (where change = Se1 month – Sebaseline). 
  
 In regression models, the change in lung nutrient concentration was 
regressed on the change in plasma nutrient to quantify the extent to which 
changes in the systemic circulation compartment predicted changes in the 
lung compartment (Table 3.3). A one-unit increase in the change in plasma -
tocopherol predicted a 0.89 unit increase (p = 0.1487) in the change in BALF 
-tocopherol and 9.7% of the change in BALF -tocopherol was predicted by 
the change in plasma -tocopherol. Given the theory that HDL is the primary 
lipid penetrating to the lung compartment, we assessed the association of 
change in HDL -tocopherol with change in BALF -tocopherol; change in 
HDL -tocopherol explained 36.2% of the change in BALF -tocopherol and a 
one-unit increase in the change in HDL -tocopherol was associated with an 
increase of about 2 in the change in BALF -tocopherol (p = 0.0024).  
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 Extending the model, we tested for a differential association of plasma 
HDL -tocopherol change with BALF -tocopherol change by gender. Thus, an 
interaction term was added to the model (change in HDL -tocopherol x 
gender). The regression coefficient for the interaction was borderline 
statistically significant (p = 0.0678); in men a one-unit increase in change in 
HDL -tocopherol predicted a 1.6 unit increase in change in BALF -
tocopherol; in women a one-unit increase in change in HDL -tocopherol 
predicted an 11.6 unit increase in change in BALF -tocopherol.  
 The association of change in plasma selenium with change in BALF 
selenium was statistically significant (p = 0.0057) and change in plasma 
selenium predicted 32.4% of the change in the BALF selenium. A one-unit 
increase in change in plasma selenium was associated with an 8.4 x 10-4 unit 
increase in change in BALF selenium, with the size of the coefficient reflecting 
the overall low concentrations of selenium in BALF. 
 
Table 3.3 Ordinary least squares regression analysis of the change in BALF nutrient 
regressed on change in plasma nutrient for 16 participants in the active intervention 
group* 
 
Nutrient 
Regression 
coefficient 
Standard 
Error 
 
P value 
 
% R-squared   
Plasma total -
tocopherol 
0.89 0.596 0.1487 9.7 
HDL -
tocopherol 
1.94 0.559 0.0024 36.2 
Selenium 
 
0.0008 0.0003 0.0057 32.4 
*Unadjusted models 
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Potential to Benefit 
 Further exploration of potential to benefit from supplementation was 
considered by using the median split to divide the participants in the active 
intervention arm into categories of ―high‖ or ―low‖ baseline values with respect 
to each of the three nutrients under consideration. Cross-classifying the three 
nutrients, six participants had low pre-supplementation plasma levels for > two 
nutrients. All six participants were also in the upper half of the distribution on 
plasma and/or urine F2-isoprostanes, and 3 of them were of particular interest 
given their very high F2-isoprostane levels at study baseline (shown by red 
lines on Figures 3.10 and 3.11). Plasma and urine F2-isoprostanes were 
considered separately because they were only moderately correlated (r = 
0.24; p = 0.31), reflecting the tissue-specific generation of F2-isoprostanes.(31) 
   
 
 
Figure 3.10 Change in plasma F2-isoprostanes during 30-day intervention; red 
line indicates greatest potential to benefit from antioxidant supplementation. 
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Figure 3.11 Change in urinary F2-isoprostanes during 30-day intervention; red 
line indicates greatest potential to benefit from antioxidant supplementation; 
dashed line indicates a non-compliant placebo participant with a sharp 
increase in vitamin C intake. 
  
 The participant with high starting plasma F2-isoprostane concentrations 
(0.252 ng isoprostanes/ml plasma vs. baseline average for all participants 
0.064 ng isoprostanes/ml plasma) had the most change with antioxidant 
supplementation; a 66.3% decrease in plasma F2-isoprostane concentrations 
was observed. 
 The two active arm participants with the highest starting concentrations 
of urine F2-isoprostanes are also low on plasma antioxidants measured at 
study baseline. Urine isoprostanes decreased 43.6% and 55.2% with 
antioxidant supplementation, supporting the hypothesis that participants with 
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the highest starting level of oxidants have the greatest potential to benefit from 
intervention.  
 
Discussion 
 In this small, in-depth study of antioxidant supplementation and 
systemic and lung-specific compartmentalization of antioxidants, 
supplementation with vitamins E and C and selenomethionine increased 
plasma concentrations of all three nutrients and lung concentrations of -
tocopherol and selenium (lung vitamin C was not assayed). The change in 
plasma selenium was strongly associated with the change in lung selenium, 
and explained about 32% of the variance in the former. Changes in plasma 
HDL -tocopherol concentrations had a strong association with change in lung 
-tocopherol concentrations, whereas the change in plasma -tocopherol was 
a poor predictor of lung compartment changes; change in plasma HDL -
tocopherol explained four times the variance in the outcome compared to 
plasma -tocopherol. This finding agrees well with cell culture and animal 
studies, which identified HDL cholesterol as the primary transport molecule 
delivering -tocopherol to alveolar type II cells in the lung.(32-34) The 
association was 10-fold stronger in women vs. men, but this finding is based 
on small number (n=3 women in sample), thus caution is appropriate in 
considering whether a sex-specific mechanism may be at play in vitamin E 
transport to the lung. 
 Prior work suggests that vitamin E supplementation decreases systemic 
oxidative stress, as represented by F2-isoprostane concentrations, only when 
the baseline urine concentrations of the analyte are > 400 pg/mg 
creatinine.(35) In considering this hypothesis, only 3 participants in the current 
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study had starting levels in the range that identified a stronger potential to 
benefit. Exploratory analyses confirmed that these 3 participants each had > 2 
nutrient values that were also low, perhaps indicating a contributing factor to 
the high oxidant stress load, although cross-sectional data at the baseline 
preclude a definitive cause-effect statement. Finally, participants with very high 
starting levels of F2-isoprostanes, in either plasma or urine, benefitted the 
most from antioxidant supplement intervention, as evidenced by the greatest 
pre-post change in F2-isoprostane. 
 Several prior studies reported -tocopherol concentrations in BALF, 
and there is good agreement with the values reported herein; BALF -
tocopherol concentrations in these studies ranged from 20-26 nmol/L, similar 
to study baseline and substantially lower than the 36.1 nmol/L concentration 
attained by active intervention arm participants at the post-supplementation 
time point.(12;13;36;37) Although one prior supplementation study reported no 
change in BALF -tocopherol after supplementation, participants were 
supplemented with only 100 mg/day of supplementation for one week and no 
information on baseline BALF -tocopherol concentration measurements was 
provided, thus the study design was weak.(12) No prior studies report 
selenium concentrations in BALF, thus this study adds normative values and 
novel data on the response of the lung compartment to supplementation.  
 Tissue-specific data are useful in assessing the extent to which the 
active substance reaches the target, and in association with less invasive 
markers may also help identify the most informative systemic biomarkers. Very 
few studies directly assess tissue-level changes in response to interventions, 
thus this study is novel in the direct measurement of the lung-compartment 
changes in nutrient status in response to supplementation of nutrients with 
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antioxidant properties. The increases in lung nutrient concentrations post-
supplementation provide support for the proposed role of dietary and 
supplemental nutrients with antioxidant properties in lung disease 
pathogenesis.    
 Several limitations of this study deserve mention. Firstly, the study was 
one month long, and a longer intervention period may have yielded larger 
changes in plasma and BALF nutritional status, particularly for selenium which 
incorporates into the body‘s tissue slowly, and is not expected to reach a 
steady state for 10-12 weeks.(38;39) However, trade-offs in participant 
retention and length of supplementation had to be balanced and the decision 
to supplement for one month was considered optimal. The assessment of 
compliance to study supplement was incomplete, and fewer than 50% of study 
participants returned the pill case at the end of the study; in all instances, 
returned cases indicated good to excellent adherence to the supplementation 
regimen. While it would have been optimal to assay a biomarker of oxidative 
stress in the lung compartment, for example via exhaled breath condensates, 
limited resources and subject burden issues prohibited such measurements. 
Finally, we omitted the two participants who were completely non-compliant to 
study supplementation from the active arm of the study; although this violates 
the intent-to-treat principle, in light of the small overall number of participants 
the ―as-treated‖ analysis is assumed to be less noisy and we were most 
interested in not missing an effect if one was present. 
 A number of strengths of this study also deserve mention. Quantitative 
methods to measure -tocopherol and selenium were sensitive, accurate and 
precise. Measurement of plasma and lung concentrations of nutrients before 
and after intervention is a substantial strength of this study and a novel 
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contribution to the literature in this area. The consideration of potential to 
benefit provided additional insights into the findings, and while too small to be 
definitive these analyses help set the stage for further research questions. 
 In conclusion, oral supplementation with vitamins E and C and 
selenomethionine leads to increases in the concentrations of nutrients in the 
plasma and in the lung compartment. The change in HDL -tocopherol is 
strongly correlated with the change in BALF -tocopherol, which provides 
interesting insights into the transport mechanisms for vitamin E. This study 
provides evidence to support the hypothesis that supplemental antioxidants 
may directly protect the lung tissue from oxidative stress, thereby supporting 
interventions with antioxidants as a means to reduce disease risk. 
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CHAPTER 4 
DIFFERENTIAL EXPRESSION OF VITAMIN E AND  
SELENIUM-RESPONSIVE GENES BY DISEASE SEVERITY IN  
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
 
Abstract 
Background: Antioxidant nutritional status has been shown to influence 
chronic obstructive pulmonary disease (COPD) susceptibility and progression. 
Prior studies document the relation of vitamin E and selenium to gene 
expression, but there are no data on the specific role of these genes in COPD. 
We hypothesized that antioxidant status is compromised in patients with 
COPD in a dose-response pattern with increasing disease severity, and that 
genes responsive to nutrients with antioxidant function are differentially 
expressed in a similar pattern. 
Methods: Lung tissue samples from COPD patients with varying disease 
severity were assayed for vitamin E and gene expression, and selenium and 
vitamin E were determined in corresponding plasma samples. Participants 
were grouped by disease severity into: 1. moderate, severe, very severe 
COPD; or, 2.mild COPD and at-risk/normal. Gene expression profiles were 
compared to identify differential gene expression by group, considering all 
microarray data in a discovery analysis. Further hypothesis-oriented analyses 
investigated gene lists as follows: genes differentially expressed in COPD, 
genes identified by GWAS of COPD, and genes differentially expressed in 
relation to vitamin E or selenium. 
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Results: Vitamin E concentrations in the lung tissue of 22 COPD patients 
were strongly associated with disease stage, and moderate/severe/very 
severe COPD cases had lower tissue vitamin E levels compared to the 
mild/at-risk group (p = 0.0082); neither plasma vitamin E nor plasma selenium 
concentrations differed by disease group. In the discovery phase, considering 
genome-wide array data, no genes were statistically significantly differentially 
expressed by disease group. In the hypothesis-oriented phase, 16 of the 109 
genes investigated were differentially expressed by COPD disease severity 
group (comparing moderate/severe/very severe COPD group to the mild 
COPD/at-risk group), with false discovery rate (FDR) q-values < 0.05. Of these 
16 genes, six were selenium-responsive genes; four genes were down-
regulated (fold-change range: -1.18, -1.39) and two genes were up-regulated 
(fold-change range: 1.54, 2.25). Six vitamin E-responsive genes were 
identified; five genes were down-regulated (fold-change range: -1.16, -2.30) 
and one gene was up-regulated (fold-change: 1.51). Three genes with prior 
evidence of a relation to COPD were confirmed; two genes were down-
regulated (fold-changes: -1.26 and -1.88) and one gene was up-regulated 
(fold-change: 1.52). A single gene identified as a COPD susceptibility gene in 
completed GWAS was up-regulated (fold-change: 1.21). 
Conclusions: Vitamin E concentration in the lung tissue of COPD patients 
varied with disease severity and vitamin E-responsive genes were differentially 
expressed by disease severity. Overall, these findings suggest a causal 
mechanism for epidemiologic findings, support the hypothesis that targeted 
nutritional intervention may have therapeutic value, and underscore the 
importance of lung compartment, tissue-specific antioxidant levels in 
understanding the disease process. 
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Introduction 
 Chronic obstructive pulmonary disease (COPD) is characterized by 
progressive irreversible airflow limitation.(1) Death rates from COPD have 
been steadily rising over the last few decades and by 2020 COPD is expected 
to become the third leading cause of death in the United States.(2-4) The 
substantial costs of COPD include losses in life expectancy and quality of life 
as well as mounting costs for medical care, which were estimated at $14.5 
billion per year in the U.S. in 2000.(5;6) 
 The primary risk factor for COPD is cigarette smoking, however, 
substantial evidence points to genetic and genomic risk factors for disease 
susceptibility and progression.(1;7) Investigations of genetic risk factors for 
COPD have been conducted using candidate gene studies, genome-wide 
association studies (GWAS), and gene expression studies.(7) Candidate gene 
studies and GWAS identify genetic variants associated with COPD risk, and 
provide clues about mechanisms, and gene expression studies, either 
genome-wide or candidate-gene, provide complemetary insights into COPD 
pathogenesis by directly studying the proteome in lung tissue.(7) Gene 
expression profiling has led to advances in identification of causal 
mechanisms, identification of potentially informative biomarkers, and new 
approaches to the classification of disease phenotypes.(8) COPD is a complex 
chronic disease and new approaches to phenotype classification, beyond 
measuring pulmonary function, will lead to a deeper understanding of the 
disease process and ultimately to the identification of novel therapeutic and 
intervention targets. Recent data show that gene discovery improves when the 
association of quantitative phenotypic variables with gene expression is 
assessed in tandem with identifying differential gene expression by disease 
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category.(8) Information about genetic variation, both at the level of the gene 
sequence and gene expression, has provided important insights into COPD 
etiology.(9-22) 
 An imbalance between oxidants and antioxidants is hypothesized to 
play an important role in COPD pathogenesis.(23-25) Oxidative stress in the 
lungs of COPD patients has been demonstrated in many studies.(26-28)  
Published studies also support an important role for antioxidants, which 
defend the lung to prevent damage resulting from oxidative stress arising in 
the context of both endogenous and exogenous oxidants.(28-31) Furthermore, 
COPD patients have lower antioxidant status compared to non-diseased 
individuals, and further declines in antioxidant status are associated with acute 
exacerbations of COPD.(32;33) 
The importance of the oxidant/antioxidant balance in COPD 
susceptibility and pathogenesis is well-established. Complementary research 
evidence has identified genes responsive to manipulation of antioxidant 
nutrients.(9;34-46) An as yet unanswered question is whether antioxidant-
responsive genes are differentially expressed in the antioxidant-depleted 
environment of the COPD lung. Given the central role of oxidant/antioxidant 
balance in COPD pathogenesis, we tested the hypothesis that antioxidant 
status is compromised in patients with COPD in a dose-response pattern with 
increasing disease severity, and that genes related to antioxidant function are 
differentially expressed in COPD by level of disease severity.  
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Methods 
Participants and Specimens  
Plasma, frozen lung tissue, and RNAlater-preserved lung tissue specimens 
were obtained from the Lung Tissue Research Consortium (LTRC), a National 
Heart, Lung, and Blood Institute-sponsored tissue bank 
(http://www.ltrcpublic.com). The LTRC collects demographic, radiographic, 
and physiologic information from COPD or interstitial lung disease (ILD) 
patients undergoing surgical treatment including lung volume reduction 
surgery or lung lobectomy/wedge resection surgery. De-identified data and 
preserved specimens are available to qualified investigators. For this study, 
twenty-four sample sets were obtained from patients with a major diagnosis of 
COPD/emphysema, and patient disease status was staged using the Global 
Obstructive Lung Disease (GOLD) 2001 Initiative guidelines.(47) Gold stage 0 
indicates no obstructive lung disease based on pulmonary function testing, but 
the presence of respiratory symptoms, and is associated with the risk of 
mortality.(48) Stages 1 through 4 correspond to levels of severity of COPD 
(Table 4.1) based on objective pulmonary function testing. Although stage 0 
indicated persons at-risk of COPD in the 2001 guidelines, recently revised 
guidelines omit stage 0 given a growing consensus that most individuals do 
not progress to stage 1. Similarly, there is debate about potential over-
diagnosis of COPD using current stage 1 definitions, which use a cut-point for 
the ratio vs. using the lower limit of normal, and based on these considerations 
combined with inspection of the characteristics of patients in the stage 1 
group, stages 0/1 (indicating absent to mild disease) were combined and 
compared with stages 2/3/4 (stages 2,3, and 4 indicate clear-cut cases with 
increasing severity) in all analyses. 
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Table 4.1 Global Obstructive Lung Disease Classifications (49)  
 
Category 0* 1:  
mild 
2: moderate 3:  
severe 
4: very 
severe 
FEV1/FVC > 0.70 < 0.070 < 0.070 < 0.070 < 0.070 
FEV1 
%predicted 
>80% >80%  50% < and  
<80% 
30% < and 
 <50% 
<30%  
or <50% plus 
the presence 
of chronic 
respiratory 
failure 
Number in 
study 5 3 4 5 5 
*in original GOLD guidelines, stage 0 was defined as ―at-risk of COPD‖, and identified as 
normal spirometry with > 1 respiratory symptom (breathlessness, cough, and/or sputum 
production), but 2005 revised guidelines omitted this stage due to uncertainty about 
progression to next stages. 
 
This study was reviewed by the Institutional Review Board (IRB) of 
Cornell University, Ithaca, NY. Exempt status was conferred by the IRB based 
on the de-identification of all samples and specimens provided by the LTRC. 
Tissue Nutrient Status Determination 
Gas Chromatography Mass Spectrometry (GC-MS) Determination of -
tocopherol 
Plasma Total -tocopherol Sample Preparation 
Briefly, 3 l of a 9--tocopherol internal standard (99 mol/L stock 
solution) was added to 75l of plasma. 150 l of ethanol was added, then 
vortexed. To extract lipids 75 l of methyl-tert-butylether and 1.0 ml hexane 
were added and sample was shaken for 2 minutes. Samples were centrifuged 
at 15,000 rpm for 1 minute then the upper hexane phase was transferred to a 
small vial. The hexane was evaporated to dryness under a nitrogen stream 
and in a 30°C water bath. The residues were silylated in 40 l pyridine 
(Thermo Scientific) and 40 l N,O-bis[trimethylsilyl]trifluoroacetimide (Thermo 
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Scientific). The headspace was flushed with nitrogen then samples were 
tightly capped and placed in a 75°C dry oven for 25 minutes. 
High Density Lipoprotein (HDL) -tocopherol Sample Preparation 
20 l of HDL cholesterol precipitating reagent (Stanbio) was added to 
150 l of plasma and allowed to stand for 5 minutes, then centrifuged at 
15,000 rpm for 1 minute. 75 l of supernatant was transferred to a tube; then 
the procedure for plasma total -tocopherol was followed. 
Lung Tissue -tocopherol Sample Preparation 
A 30-70 mg piece of lung tissue was sub-sampled from a frozen lung 
tissue sample without thawing. The frozen sample was weighed in a tared 
culture tube prior to addition of 2 ml isopropanol, 5 l of a 9-tocopherol 
internal standard (99 mol/L stock solution), and 1 ml 0.9% saline solution. 
The contents of the tube were then homogenized for 15-20 seconds using a 
Polytron homogenizer. The resulting suspension was transferred to a screw 
cap tube. The homogenizing tube was rinsed with 1 ml methyl-tert-butylether 
and homogenized for 5-10 seconds. The rinse solvent was added to the screw 
cap tube, followed by addition of 3 ml hexane. The tube was shaken for 2 
minutes then centrifuged at 15,000 rpm for 2 minutes. The solvent phase was 
transferred to a new tube, concentrated to 1 ml under a nitrogen stream, 
transferred to a 1.5 ml screw cap vial, and evaporated to dryness under 
nitrogen in a 30°C water bath. The lipid residue was silylated in 40 l pyridine 
(Thermo Scientific) and 40 l N,O-bis[trimethylsilyl]trifluoroacetimide (Thermo 
Scientific). The headspace was flushed with nitrogen then samples were 
tightly capped and placed in a 75°C dry over for 25 minutes. 
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GC-MS Determination of Tocopherols 
Alpha-tocopherol concentrations in plasma (total and HDL) and lung 
tissue samples were determined by GC-MS, using a Hewlett Packard 6890 
gas chromatograph coupled to a Hewlett Packard 6890 mass spectrometer. 
Tocopherols were resolved isothermally at 280°C on an HP-1 capillary column 
(Agilent Technologies) operated in split injection mode with helium as the 
carrier gas. Detection was by selected ion monitoring (SIM mode). Tocopherol 
and free cholesterol (as silyl ethers) were quantitated against the 9--
tocopherol internal standard, adjusting the cholesterol values for pre-
determined differences in detector response.  
Plasma samples were assayed in duplicate for total -tocopherol with 
average coefficient of variation (CV) of 4.2%; the CV was 2.4% after adjusting 
for cholesterol (as measured within the GC-MS method). HDL -tocopherol 
was measured in single samples due to sample volume limitations. The typical 
CV for the HDL method is 13.2%, and 4.0% after adjusting for cholesterol (as 
measured within the GC-MS method). Lung tissue samples were run on single 
samples due to limited tissue sample amounts, and -tocopherol 
concentrations were not adjusted for cholesterol due to heterogeneity of lung 
tissue samples. 
All vitamin E assays were completed (by AHA) in the Division of 
Nutritional Sciences, Cornell University, Ithaca, NY. 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Determination of 
Selenium 
Plasma Selenium Sample Preparation 
A 2% nitric acid solution was prepared using concentrated nitric acid 
from a Teflon sub-boiling still and double-deionized water, resistivity > 18 M 
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cm. Plasma samples were prepared for selenium analysis by adding 5 ml of 
2% HNO3 to 100 l of plasma (thawed at room temperature). Two reference 
standard solutions, 1 ppb and 5 ppb, were run at regular intervals throughout 
sample testing and average concentrations were determined to be 1.002 ppb 
and 5.117 ppb, respectively with standard deviations of 0.023 and 0.073, 
respectively. Seronorm Trace Elements, Serum, Levels I and II (Accurate 
Chemical & Scientific Corp., Westbury, NY) and two NBS standard samples 
were used as reference materials for method validation and assessment of 
accuracy and precision. Seronorm and NBS samples were prepared in the 
same way as the plasma samples and run at regular intervals throughout 
sample testing. All four reference materials were determined to have values 
within the range of acceptable results for the material.  
ICP-MS Determination of Total Plasma Selenium 
An Agilent 7500 cs/ce quadrupole ICP-MS equipped with a collision 
reaction cell was used to determine selenium concentration in plasma 
samples. The ion intensity at m/z 78 was used to monitor Se and 89Y was 
used as an internal standard for plasma samples. Data was collected using 
the Spectrum mode for direct analysis. Maximum sensitivity was obtained by 
daily tuning of the ion lens system, gas flow rates, and other parameters. 
Samples were run manually with continuous quality monitoring. Table 4.2 
summarizes the operating conditions and instrumental parameters.  
Sample preparation and analysis was performed at the USDA Plant, 
Soil & Nutrition Laboratory, Cornell University, Ithaca, NY. 
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Table 4.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) operating 
conditions and instrumental parameters for plasma selenium determination 
Parameter Value 
RF power 1400 Watts 
Sample uptake rate 2.5 ml/min 
Reaction mode He or H2, 5 ml/min, Spectrum mode 
Gas flow rates:  
Plasma gas Ar,  
Auxillary gas 0 L/min 
Carrier gas Ar, 0.8 L/min 
Makeup gas Ar, 0.45 L/min 
Ion sampling depth 8 mm 
Torch Quartz 2.5 mm id fitted with Agilent ShieldTorch system 
Nebulizer Microliter nebulizer, Microglass (Cedar Ridge, CO) 
Sample cone Pt, orifice diameter 1.0 mm 
Skimmer cone Pt, orifice diameter 0.4 mm 
Spray chamber Double cyclonic and water cooled Scott type 
Integration time  0.2000 sec 
Sampling period 0.6000 sec 
Sweeps per reading 40-60 
 
Chemiluminescence Determination of Plasma Cholesterols and Triglycerides 
Total, HDL, and LDL cholesterol and triglycerides were determined 
using chemiluminescence under standard methods on a Siemens Dimension 
Xpand, a Center for Disease Control and Prevention-certified instrument. 
Average within-run and between-run CVs for the analytes were as follows: 
total cholesterol, 0.71% and 1.94%; HDL cholesterol, 0.36% and 4.20%; LDL 
cholesterol, 0.48% and 3.10%; and triglycerides, 0.28% and 2.12%. Two 
control samples, Biorad Liquid Assayed Multiqual Level 1 and Level 3, were 
assayed and all values for the lipids were determined to be within the 
acceptable range. 
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Cholesterol and triglyceride measurements were performed in the 
Francis Johnston and Charlotte Young Human Metabolic Research Unit, 
Cornell University, Ithaca, NY. 
Determination of Gene Expression in Lung Tissue Samples 
Extraction of RNA from Lung Tissue Samples 
 Frozen RNAlater preserved lung tissue samples were thawed at room 
temperature prior to excising 30 mg subsamples, which were added to tared 
Eppendorf tubes that were then re-weighed to determine exact sample mass. 
With the samples on ice at all times 0.9 ml aliquot of TRIzol was added to 
each tube prior to homogenization with a Kontes Pellet Pestle Motor with a 
disposable Pellet Pestle. Homogenization was complete when large tissue 
pieces were no longer visible, typically within 15 seconds. Samples were 
incubated for 5 minutes at room temperature. 
 To the homogenized samples, 0.2 ml of choloroform was added then 
the sample were capped, shaken vigorously by hand for 15 seconds, and 
allowed to incubate at room temperature for 2-3 minutes. Samples were 
centrifuged at 10,000 x g for 10 minutes. The upper aqueous phases were 
transferred to RANse-free 1.5 ml Eppendorf tubes; the remaining interphase 
and phenol-choloroform phase was retained and stored at -20°C. To the 
aqueous phases 500 l of 100% ethanol was added then tubes were capped 
and gently inverted 4-5 times. For each sample, a 700 l aliquot was added to 
an RNeasy MinElute spin column placed atop a 2 ml collection tube (RNeasy 
MinElute Cleanup Kit, Qiagen) and the column was capped and centrifuged at 
14,000 x g for 15 seconds. The flow-through from the collection tube was 
discarded and the remaining volume of the aqueous phase/ethanol mixture 
was added to the column, again centrifuging the column and discarding the 
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flow-through from the collection tube. 500 l of Buffer RPE was pipetted onto 
the spin column (RNeasy MinElute kit, Qiagen) and the column was 
centrifuged at 14,000 x g for 15 seconds, with flow-through discarded. 500 l 
of 80% ethanol was added to the spin column, which was then centrifuged at 
14,000 x g for 2 minutes followed by discarding of the flow-through and the 
collection tube. The RNeasy MinElute spin column was placed in a new 2 ml 
collection tube with the column lid open and then centrifuged at maximum 
speed for 5 minutes. The flow-through and collection tube were discarded. The 
column was transferred to a new RNAse free 1.5 ml Eppendorf tube and 18 l 
of 1X RNASecure (Ambion) was pipetted onto the gel membrane of the 
column. The column was centrifuged for 1 minute at maximum speed.  
The resulting sample volumes were assessed and recorded. RNA 
eluate aliquots of 1 l from each sample were added to new, labeled RNAse 
free 1.5 ml Eppendorf tubes containing 2 l of DEPC-treated water. Additional 
aliquots of each RNA sample were assessed to visualize and quantify the 
degree of RNA integrity using an Agilent Bioanalyzer (Aglient Technologies, 
Palo Alto, CA). Two samples, one from a GOLD 1 patient and one from a 
GOLD 2 patient, produced RNA of insufficient quality for use on the 
microarrays; these samples were removed from the microarray preparation 
pipeline. RNA concentrations for the remaining 22 samples were determined 
using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE).  
Microarray Preparation and Processing 
 Using Affymetrix kits (Santa Clara, CA) beginning with the GeneChip 
One-Cycle cDNA Synthesis Kit, 3 mg of total RNA was used to synthesize 
double stranded cDNA, followed by cleanup with GeneChip Sample Cleanup 
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Module, in vitro transcription (IVT) reaction using GeneChip IVT Labeling Kit, 
and clean-up and quantification of the biotin-labeled cDNA yield by 
spectrophotometric analysis. Hybridization to test chips and the microarrays 
were performed according to Affymetrix protocols, using Affymetrix 
microarrays HG-U133 Plus 2.0 (54,675 probe sets). Microarrays were 
processed by the Affymetrix fluidics station and scanned with the Affymetrix 
GeneChip Scanner 3000 7G. Quality of microarrays was assessed by the 
following criteria: 1) RNA Integrity Number (RIN) ≥6.0; 2) 3’/5’ ratio for GAPDH 
≤3; and 3) scaling factor ≤10.0.(50) Using Bioconductor version 2.7 (R version 
2.12.0) the Microarray Suite version 5.0 (MAS 5.0) algorithm (Affymetrix) was 
used to analyze the captured images and assess microarray quality.  
 RNA extraction and microarray preparation and processing were 
conducted at Weill Cornell Medical College, Department of Genetic Medicine, 
New York, NY. 
Statistical Analysis 
 Analytical measurements for nutrients are reported as means with 
standard deviations and group means were compared using t-tests. All data 
management and analysis was conducted in SAS version 9.2 (SAS Institute, 
Cary, NC). 
GC-RMA normalization of the expression data was performed using 
quantile normalization with expression estimates calculated with the empirical 
Bayes estimate for non-specific binding. Processed images from the 
microarrays were used to redefine probe sets by using up-to-date databases 
to annotate probes and assign unique gene identifiers (Entrez IDs). Using the 
Bioconductor Limma package, differentially expressed probe sets were 
identified using linear models that apply moderated t-statistics that implement 
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empirical Bayes regularization of standard errors. Comparisons were made 
between GOLD 2-4 and GOLD 0-1 using the fold-change threshold method. 
 In addition to a discovery-based genome-wide analysis, four lists of 
genes were compiled to test for differences in gene expression by disease 
status based on a hypothesis-oriented approach. The first gene list (Table A2) 
comprised genes identified by prior studies of expression in COPD patients 
compared to controls; confirming this list in the current study allowed 
consideration of the validity of the samples and methods.(18;19) The second 
gene list (Table A2) comprised genes identified as COPD susceptibility genes 
in published genome-wide analysis studies (GWAS).(10;11;13;14;51) The third 
and fourth gene lists (Table A2) related specifically to the hypotheses about 
oxidant/antioxidant balance and comprised antioxidant-responsive genes. The 
initial selenium-responsive gene list was prepared by reviewing 17 studies 
published in the literature, yielding a list of 111 genes. Similarly, review of 12 
published studies generated an initial vitamin E-responsive gene list that 
contained 102 genes. The literature reviews encompassed studies in cell and 
animal models as well as human intervention trials. Undertaking a gene-by-
gene in-depth review, each list was curated for biologic relevance to the 
present study. Genes were retained if they were known to be expressed in 
lung tissue, if they were expressed under relevant physiologic concentrations 
of the nutrient, if expression was not limited to highly specific physiologic 
stress conditions, and if they were not primarily related to cancer processes. 
The final gene lists (Table A2) comprised 42 selenium-responsive genes from 
7 published studies and 42 vitamin E-responsive genes from 6 published 
studies.(9;34-36;38-46)  
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Using p-values from the microarray analysis, FDR q-values were 
estimated for genes in each of the gene lists in SAS. Genes were considered 
differentially expressed if fold change > 1.15, p-value < 0.05, and q-value < 
0.05. Finally, for genes with evidence of differential expression, further 
analyses assessed the association of gene expression with tissue and plasma 
nutrient concentrations with the Pearson product moment correlation 
coefficient.  
 Gene Set Enrichment Analysis (GSEA) was used to identify whether 
changes in gene expression were associated with functional changes (Broad 
Institute, Cambridge, MA). GSEA is based on pre-defined groups of genes that 
share biological function, regulatory mechanisms, or chromosomal location 
(Subramanian). The analysis was run using 1000 permutations per gene 
pathway and gene pathway sizes were restricted to between 15 and 500 
genes per pathway. A total of 234 pathways were evaluated, and the FDR q-
value, normalized enrichment score (NES), and nominal p-values were used 
to assess whether the pathway was statistically significantly differentially 
regulated in lung tissue samples from GOLD stage 2-4 patients compared to 
GOLD 0-1 patients. Gene pathways with a nominal p-value <0.01 and an FDR 
q-value <0.10 were considered statistically significant. 
 
Results 
Participant Characteristics 
 High quality RNA samples were obtained from 22 of the 24 lung tissue 
samples, and thus two patients were not included in further analysis. The 
remaining 22 participants (Table 4.3) comprised 14 males and 8 females and 
all but two participants were non-Hispanic White (1 African American male, 1 
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Hispanic male). All participants were past or current cigarette smokers with an 
average of 58.6 pack-years of cigarette smoking (1 pack cigarettes/day for one 
year = 1 pack-year). Participants with severe COPD (GOLD stage 4) tended to 
be younger than average, which may indicate a genetic predisposition to early 
onset COPD due to -1-antitrypsin deficiency.(16) 
 
Table 4.3 Characteristics of twenty-two patients providing tissue samples 
obtained through the Lung Tissue Research Consortium, National Heart, 
Lung and Blood Institute, stratified by Global Obstructive Lung Disease 
(GOLD) Stage 
 
  GOLD Stages 
GOLD Stages 
Grouped 
 Total 0 1 2 3 4 0/1 2/3/4 
N= 22 5 3 4 5 5 8 14 
Age, years* 
66.5 
(0.6) 
73.8 
(8.3) 
68.5 
(9.0) 
71.4 
(3.6) 
63.4 
(10.6) 
55.6 
(2.8) 
71.4 
(8.6) 
63.5 
(9.1) 
Sex, 
male/female 
14/8 4/1 3/0 2/2 2/3 3/2 7/1 7/7 
Pack-years 
smoking* 
58.6 
(38.2) 
64.8 
(38.9)
†
 
47.8 
(25.4) 
70.8 
(74.4) 
42.8 
(4.8) 
68.6 
(9.5) 
56.2 
(31.7) 
60.7 
(42.2) 
Years since 
quitting 
smoking* 
8.6 
(10.4) 
21.0 
(14.3)
†
 
7.0 
(14.0) 
7.0 
(8.7) 
6.8 
(4.0) 
3.4 
(2.5) 
14.0 
(15.1) 
5.7 
(5.6) 
 
*Continuous variables reported as mean (SD)  
 
†
One participant was missing smoking data and is not included in the mean or SD 
 
Tissue Nutrient Status 
 Plasma total selenium, total -tocopherol, HDL -tocopherol and lung 
tissue -tocopherol levels were measured in all samples (Table 4.4), and were 
examined for trends by GOLD stage. There was little variation in average 
plasma selenium levels by GOLD stage, and the mean selenium in GOLD 0-1 
(no disease and minimal disease) vs. 2-4 (moderate/severe/very severe) was 
not statistically significantly different (p = 0.24). Plasma -tocopherol and HDL 
-tocopherol varied by GOLD stage such that -tocopherol concentrations 
were higher in GOLD 0/1 and lower in GOLD 4. However, when the GOLD 0/1  
83 
 
 
Table 4.4 Nutritional status of twenty-two patients providing tissue samples 
obtained through the Lung Tissue Research Consortium, National Heart, Lung 
and Blood Institute, stratified by Global Obstructive Lung Disease (GOLD) 
Stage* 
 
 
 GOLD Stages 
GOLD Stages 
Grouped 
  
Total 0 1 2 3 4 0/1 2/3/4 
N= 22 5 3 4 5 5 8 14 
Plasma Selenium, 
mg Se/L plasma 
181.8 
(29.5) 
165.3 
(17.6) 
182.6 
(59.9) 
187.8 
(37.8) 
182.7 
(19.3) 
192.2 
(23.0) 
171.8 
(35.8) 
187.5 
(25.0) 
Plasma -
tocopherol, mol 
-toc/mmol 
cholesterol 
24.4 
(11.9) 
30.9 
(18.8) 
21.6 
(8.2) 
27.4 
(13.1) 
24.0 
(7.5) 
17.5 
(5.7) 
27.4 
(15.6) 
22.7 
(9.4) 
HDL -tocopherol, 
mol -toc/mmol 
cholesterol 
23.5 
(8.4) 
30.0 
(9.5) 
16.8 
(1.6) 
22.7 
(8.1) 
24.3 
(9.2) 
20.6 
(6.5) 
25.1 
(10.0) 
22.5 
(7.5) 
Tissue -
tocopherol, nmol 
-toc/g lung tissue 
39.2 
(14.6) 
47.9 
(12.1) 
52.3 
(19.7) 
36.5 
(5.7) 
38.5 
(13.8) 
25.4 
(10.0) 
49.5 
(14.1) 
33.2 
(11.6) 
*All values reported as mean (SD) 
  
group was contrasted with the GOLD 2/3/4 group, the difference in means was 
not statistically significant for either plasma or HDL -tocopherol (p=0.38 and 
p=0.51, respectively), but GOLD 0/1 patients had higher levels of antioxidants 
on average in comparison to GOLD 2/3/4 patients. Nineteen of 22 plasma 
samples analyzed by GC/MS for -tocopherol displayed a peak that is 
characteristic of dietary supplementation with all-rac--tocopherol acetate 
(synthetic -tocopherol). One participant each in GOLD 2, 3, and 4 had no 
evidence of synthetic -tocopherol supplementation. Lung tissue -tocopherol 
concentration was similar in GOLD 0 and GOLD 1, and steadily lower with 
increasing disease severity. When the combined GOLD 0-1 (49.5 nmol/g) and 
GOLD 2-4 (33.2 nmol/g) categories were compared, tissue -tocopherol 
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concentrations were statistically significantly different (p=0.0082). The clear 
separation in lung tissue -tocopherol concentration supported combining 
GOLD 0-1 and GOLD 2-4 into two discrete categories for further investigation 
of gene expression differences, particularly given the interest in 
antioxidant/oxidant balance in this study. Plasma and tissue -tocopherol 
concentrations were moderately correlated (r=0.44; p=0.04). 
Analysis of Gene Expression by GOLD Stage Groups 
 A genome-wide array analysis was conducted first. Five genes were 
differentially expressed in GOLD 2/3/4 with nominal p-values <0.0001, but the 
lowest false discovery rate (FDR) q-value was 0.27. The 25 genes with the 
lowest p-values are shown in Appendix Table A3; none of the top 25 genes 
were on any of the hypothesis-oriented gene lists. 
In the hypothesis-oriented analyses, four gene lists were developed, as 
described above, including: 1) COPD GWAS genes (6 genes), 2) COPD 
differential expression genes (22 genes), 3) vitamin E-responsive genes (42), 
and 4) selenium-responsive genes (42 genes). Overall, the gene lists 
comprised 109 unique genes, and 3 genes appeared on two lists (Appendix 
Table A3). SERPINE2 was on both the COPD GWAS list and the COPD 
differential gene expression list. COL1A1 and TNF were on both the COPD 
differential gene expression list and the vitamin E-responsive gene list.  
  One gene from the COPD GWAS list, three genes from the COPD 
differential gene expression list, and six genes each from the vitamin E-
responsive and selenium-responsive lists were differentially expressed in 
GOLD 2/3/4 lung tissue samples compared to GOLD 0/1 with FDR q-value 
<0.05 (Table 4.5).  
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Table 4.5 Genes differentially expressed in GOLD Stage 2/3/4 lung tissue 
compared to GOLD Stage 0/1 lung tissue, FDR q-value < 0.05  
 
Gene list Gene 
symbol 
Gene name Fold change* Raw p-
value 
FDR q-
value
†
 
COPD 
GWAS 
BICD1 Bicaudaul D 
homolog 1 
1.21 0.025 0.0251 
COPD gene 
expression 
PLAUR Plasminogen 
activator, 
urokinase 
receptor 
-1.88 0.015 0.0426 
VEGFB Vascular 
endothelial 
growth factor 
-1.26 0.025 0.0426 
MMP2 Matrix 
metalloproteinase 
2 
1.52 0.034 0.0426 
Vitamin E 
responsive 
TNNI2 Troponin 1 type 2 -1.34 0.007 0.0241 
KRT1 Keratin 1 1.51 0.019 0.0241 
SRA1 Steroid receptor 
RNA activator 1 
-1.16 0.019 0.0241 
PPARG Peroxisome 
proliferator-
activated 
receptor gamma 
-1.76 0.019 0.0241 
SULT2B1 Sulfotransferase 
famly cytosolic 
2B member 1 
-1.42 0.026 0.0271 
KRT4 Keratin 4 -2.30 0.036 0.0303 
Selenium 
responsive 
NR2F1 Nuclear receptor 
subfamily 2 group 
F member 1 
1.54 0.003 0.0347 
SELT Selenoprotein T -1.18 0.003 0.0347 
P4HA1 Prolyl 4-
hydroxylase 
alpha polypeptide 
-1.31 0.007 0.0347 
MS4A1 Membrane 
spanning 4 
domains 
subfamily A 
member 1 
2.25 0.008 0.0347 
GNGT2 Guanine 
nucleotide-
binding protein 
subunit gamma 2 
-1.39 0.009 0.0347 
GSTO1 Glutathione S-
transferase 
omega-1 
-1.23 0.010 0.0347 
*Log2 fold change 
†
Estimated for each gene list individually 
 
The BICD1 gene from the COPD GWAS gene list was significantly up-
regulated in GOLD 2-4 lung tissue. Two other genes, which have generated 
significant interest in recent GWAS, HHIP and SERPINE2, had an FDR q-
value < 0.05 and fold-changes of -1.32 and -1.44, respectively, but nominal p 
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values did not meet preset criteria (p values were 0.118 and 0.1396, 
respectively; Table 4.5). In the COPD gene expression list, PLAUR and 
VEGFB were down-regulated and MMP2 was up-regulated in the GOLD 2/3/4/ 
group vs. GOLD 0/1 (Table 4.5).  
 Five out of six vitamin E-responsive genes with evidence of differential 
expression were down-regulated in GOLD 2/3/4 lung tissue samples 
compared to GOLD 0/1; KRT1 was up-regulated with fold-change of 1.51. 
Fold-changes of down-regulated vitamin E-responsive genes ranged from -
1.16 to -2.30 (Table 4.5). Two selenium-responsive genes, NR2F1 and 
MS4A1, were up-regulated in GOLD 2/3/4 lung tissue samples compared to 
GOLD 0/1, with fold-changes of 1.54 and 2.25, respectively. The remaining 
four selenium-responsive genes with statistically significant evidence of 
differential expression by GOLD stage were down-regulated; fold-changes 
ranged from -1.18 to -1.39 (Table 4.5).  
For the 16 genes that were differentially expressed by GOLD stage 
disease severity groups, the association of nutrient concentrations in lung 
tissue and plasma with gene expression was assessed (Table 4.6). For four 
genes, expression was correlated with more than 1 nutrient (p<0.05). The 
expression of plasminogen activator, urokinase receptor (PLAUR) was 
positively associated with lung tissue vitamin E (r=0.46; p=0.03) and plasma 
vitamin E (r=0.66; p=0.0008), respectively.  PPARG, peroxisome proliferatior-
activated receptor gamma, which was documented to be responsive to vitamin 
E in prior studies, was associated with vitamin E plasma levels (r=0.46; 
p=0.03). Several genes on the selenium-responsive list were associated with 
vitamin E nutriture, as follows: guanine nucleotide-binding protein subunit 
gamma 2, GNGT2, (r=0.65, p=0.0010 for plasma; r=0.53, p=0.01 for lung); 
87 
 
propyl 4-hydroxylase alpha polypeptide, P4HA1 (r=0.41, p = 0.055 for 
plasma). 
 
Table 4.6 Pearson Product Moment Correlations for the relation of lung tissue 
gene expression with nutritional status in lung tissue and plasma for subset of 
genes differentially expressed by GOLD Stage. 
 
Gene list Gene 
symbol 
Tissue -tocopherol Plasma -tocopherol Plasma Selenium 
  r * P value r * P value r * P value 
COPD 
GWAS 
BICD1 -.011 0.62 -0.15 0.50 0.31 (0.16) 
COPD gene 
expression 
PLAUR 0.46 0.03** 0.66 0.0008** 1.5x10
-2
 0.95 
VEGFB -4.8x10
-2
 0.83 -8.5x10
-2
 0.71 0.29 0.19 
MMP2 -9.1x10
-2
 0.69 3.6x10
-2
 0.87 -0.33 0.13 
Vitamin E 
responsive 
TNNI2 0.25 0.25 0.29 0.18 0.19 0.40 
KRT1 -0.12 0.63 -0.10 0.65 0.36 0.10 
SRA1 8.1x10
-2
 0.72 6.3x10
-3
 0.98 -0.42 0.049** 
PPARG 0.20 0.36 0.46 0.03** 0.24 0.29 
SULT2B1 -6.3x10
-2
 0.78 -8.4x10
-2
 0.71 0.27 0.23 
KRT4 5.9x10
-2
 0.80 0.34 0.12 0.34 0.12 
Selenium 
responsive 
NR2F1 -0.21 0.34 -0.21 0.35 -2.2x10
-2
 0.92 
SELT 0.22 0.33 -0.15 0.52 -0.23 0.30 
P4HA1 0.30 0.18 0.41 0.055** 2.8x10
-2
 0.90 
MS4A1 -0.17 0.45 -0.29 0.20 -0.17 0.44 
GNGT2 0.65 0.0010** 0.53 0.01** 3.2x10
-2
 0.89 
GSTO1 9.5x10
-3
 0.97 -1.3x10
-2
 0.95 -2.8x10
-2
 0.90 
 *Correlation coefficient and associated P value 
**P  < 0.05 
 
Gene Set Enrichment Analysis (GSEA) 
 GSEA was used to identify up- or down-regulated pathways using 
cutoffs of nominal p<0.05 and FDR q-value <0.10. We identified a single up-
regulated pathway and 21 down-regulated pathways, 8 of which had an FDR 
q-value <0.05 (Table 4.7). Figure 4.1 shows the enrichment plot for the IL7 
pathway. Genes to the left of the peak contribute the most to enrichment of the 
pathway, and thus to the differential expression between disease severity 
groups. Of the down-regulated pathways, 11 are related in some way to  
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Table 4.7 Gene set enrichment analysis showing pathways of genes 
differentially expressed in lung tissue from patients with GOLD Stages 2/3/4 
disease versus GOLD 0/1 
 
Pathway # Genes ES* NES* Nominal 
p-value 
FDR* q-
value 
Up-regulated pathways 
IL7  16 0.681 1.99 0.002 0.052 
Down-regulated pathways 
ATP synthesis 21 -0.641 -2.00 0.002 0.006 
Type III secretion system 21 -0.641 -2.01 0 0.006 
Flagellar assembly 21 -0.641 -1.98 0 0.006 
Pyruvate metabolism 37 -0.551 -2.03 0 0.007 
Oxidative phospholylation 58 -0.514 -2.04 0 0.007 
Photosynthesis 22 -0.63 -2.04 0.002 0.015 
Proteasome pathway 20 -0.598 -1.86 0.002 0.020 
RNA transcription reactome 36 -0.513 -1.85 0 0.022 
Glycolysis 52 -0.438 -1.72 0.002 0.055 
Inflam pathway 29 -0.498 -1.70 0.006 0.056 
Gluconeogenesis 52 -0.438 -1.71 0 0.056 
Porphyrin and cholorphyll metabolism 19 -0.579 -1.74 0.006 0.056 
Proteasome 17 -0.582 -1.73 0.006 0.059 
Ubiquinone biosynthesis 15 -0.595 -1.74 0.011 0.059 
Stem pathway 15 -0.565 -1.64 0.034 0.073 
Propanoate metabolism 31 -0.484 -1.66 0.009 0.073 
Glycolysis and gluconeogenesis 42 -0.442 -1.66 0.009 0.075 
Hytrophy model 17 -0.556 -1.65 0.017 0.075 
Krebs TCA cycle 29 -0.476 -1.64 0.006 0.076 
Mitochondrial fatty acid betaoxidation 15 -0.575 -1.62 0.027 0.077 
Cholesterol biosynthesis 15 -0.558 -1.60 0.030 0.088 
*ES – Enrichment score for the gene set; reflects the extent of over-representation of the gene 
set at the top or bottom of the ranked list; NES – Normalized enrichment score; normalized ES 
accounting for the size of the gene set; FDR – False discovery rate 
 
cellular energy synthesis and metabolism, including the most strongly down-
regulated pathway, the ATP synthesis pathway. Pyruvate metabolism, 
oxidative phosphorylation, glycolysis, gluconeogenesis, and Krebs TCA cycle 
pathways are closely related to ATP production and metabolism. In addition, 
ubiquinone biosynthesis and proteasome pathways are ATP-dependent and 
thus would down-regulate in response to down-regulation of ATP synthesis. 
Down-regulation of the inflammatory pathway, which contains many interleukin 
genes, was observed with more severe disease.  
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Figure 4.1 Enrichment plot of IL7 pathway from Gene Set Enrichment Analysis 
(GSEA); genes to the left of the Enrichment Score peak contribute most to the 
enrichment pathway, reflecting differential expression in the pathway between 
GOLD 2/3/4 lung tissue and GOLD 0/1 lung tissue 
 
Discussion 
 Based on prior studies showing differential plasma status of 
antioxidants in COPD patients compared to controls, we hypothesized that a 
lung-tissue-specific measure of antioxidant status would be correlated with 
COPD severity as assessed by GOLD stage diagnosis.(31;52) Lung tissue -
tocopherol varied by disease stage, and levels were about 33% higher in 
GOLD 0/1 patients compared to GOLD 2/3/4 patients, with a clear trend. 
Trends for plasma and HDL -tocopherol were less clear, which suggests the 
importance of considering compartment-specific nutrient levels.  Among all 
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participants, the use of supplemental vitamin E was common, as 
demonstrated by the presence of an analyte unique to supplements 
(unpublished data). Plasma selenium levels were similar by GOLD stage 
groups, and selenium could not be assayed in lung tissue due to limited tissue 
volume. Lower lung tissue levels of -tocopherol with increasing disease 
severity are consistent with two hypotheses. First, COPD is hypothesized to 
lead to lowered -tocopherol in lung tissue either because the nutrient is 
rapidly utilized in the COPD lung and/or because the transport and/or uptake 
of -tocopherol in the lung are impaired in diseased individuals. An alternative 
hypothesis, which cannot be ruled out in the current design, is that lowered 
lung tissue -tocopherol levels is a causal factor in disease development, and 
the lowered nutrient status contributes, in part, to the pathophysiology. While 
this study cannot distinguish between the two explanations, both are 
interesting in terms of identifying possible intervention targets (one preventive 
and the other therapeutic). 
 Nutrients with antioxidant properties may play a role in regulating 
genes, and there is mounting evidence for this in vitamin E and selenium-
responsive genes.(9;34-40) Thus, we further hypothesized that gene 
expression would be differentially regulated in patients with different tissue 
levels of antioxidants. When patients with GOLD stage 2/3/4 disease were 
compared to patients with GOLD stage 0/1 disease in a genome-wide array 
analysis, no genes were significant at genome-wide thresholds for statistical 
significance. These findings are limited by the small sample size in this study, 
and effect sizes for genome-wide significance would have had to be very large 
in light of the small sample size. The further analyses that pursued expression 
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differences using hypothesis-oriented gene lists identified several expression 
differences of interest.  
The BICD1 gene, bicaudaul D homolog 1, which was identified as a 
COPD susceptibility gene in a recent GWAS of COPD, was up-regulated in 
moderate/severe/very severe COPD cases.(10) Variants in BICD1 are 
associated with telomere length and the hypothesized mechanism linking 
BICD1 SNPs to COPD risk is accelerated aging, which may contribute to the 
pathogenesis of emphysema.(10;53;54) The differential expression of BICD1 
in lung tissue from COPD patients could be due to single-nucleotide 
polymorphisms (SNPs), gene-environment interactions, or other mechanisms. 
Two other genes, HHIP and SERPINE2, also identified by GWAS studies as 
COPD susceptibility genes, had FDR q-values < 0.05.(11;14;16) The finding 
that genes identified by prior GWAS studies are differentially expressed in this 
study of lung tissue from COPD patients provides complementary evidence 
supporting a causal role for these genes in COPD pathogenesis.  
Based on a literature review of studies of differential gene expression 
associated with COPD, a list of genes was identified for testing. The 
plasminogen activator, urokinase receptor gene, PLAUR was down-regulated 
(fold-change -1.88; p = 0.015; q = 0.0426) in lung tissue from GOLD 2/3/4 
patients (vs. GOLD 0/1), in contrast to a prior report that PLAUR expression 
was inversely associated with FEV1 (higher expression associated with lower 
lung function).(18) The PLAUR protein assists in the conversion of latent 
matrix metalloproteinases, such as MMP1—which is implicated in the 
pathogenesis of emphysema—by converting plasminogen to plasmin.(18) 
VEGFB, vascular endothelial growth factor B, was down-regulated (fold-
change -1.25) in GOLD 2/3/4 vs. GOLD 0/1. Gosselink et al reported on a 
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related VEGF gene, which was dysregulated in small airways, but the finding 
did not reach statistical significance thresholds thus the direction of fold-
change was not reported.(18) The matrix metalloproteinase 2 gene, MMP2, 
was up-regulated in GOLD 2/3/4 cases compared to GOLD 0/1 (fold-change 
1.52). Contrary to our findings, a prior study reported that MMP2 expression in 
small airways tissue (both the alveolar tissue and surrounding tissue) was 
directly associated with FEV1 (decreased protein associated with lower lung 
function).(18) However, consistent with our findings, an immunohistochemical 
analysis of MMP2 staining in human lung tissue reported more protein in 
relation to increasing disease severity, and MMP2 expression was inversely 
associated with the ratio of FEV1/FVC (higher expression associated with 
lower ratio).(55) Our finding supports the immunohistochemical study by 
Baraldo et al and Gosselink’s findings are at odds with both Baraldo and the 
results reported herein.(18;55) 
 Six differentially expressed genes were identified on the vitamin E-
responsive gene list when comparing expression in lung tissue from patients 
with GOLD stages 2/3/4 compared to GOLD 0/1; five were down-regulated 
and one was up-regulated. A particularly interesting gene from the vitamin E-
responsive list is peroxisome proliferator-activated receptor gamma, PPARG; 
prior studies report PPARG is upregulated by -tocopherol.(44) In lung tissue 
samples, PPARG expression was lower in patients with GOLD stages 2/3/4 
and lung tissue from these patients was also lower in -tocopherol 
concentrations, consistent with prior findings in other tissues.(44) PPARG is 
implicated in cell signaling and cell-cycle regulation and may be important in 
management of inflammatory conditions.(44) In a recently completed study of 
asymptomatic cigarette smokers supplemented with vitamins E and C and 
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selenomethionine for 30 days, the pre-post supplementation log10 fold-change 
expression of PPARG in large airway epithelial cells was 119.3 (compared to -
37.9 fold-change in the placebo group; unpublished data), supporting the 
finding that PPARG expression is responsive to vitamin E.TNNI2, troponin 1 
type 2, was down-regulated, with a fold-change of -1.34. TNNI2 is related to 
cytoarchitecture and contributes to the formation of capillaries, though 
information is sparse on vitamin E regulation of this gene.(41)  
 Six genes in the selenium-responsive list were differentially expressed 
by disease group. The nuclear receptor subfamily 2 group F member 1 gene, 
NR2F1, was up-regulated and expression levels were 1.54-fold higher in lung 
tissue samples from GOLD 2/3/4 patients compared to GOLD 0/1. A prior 
study reported that NR2F1 was down-regulated by supplemental 
selenomethionine.(34) Although plasma selenium levels do not differ much by 
GOLD groups, we were unable to measure selenium concentrations in lung 
tissue. If lung tissue selenium follows the pattern of -tocopherol, then GOLD 
2/3/4 patients are expected to have lower levels of lung tissue selenium, which 
would fit with the up-regulation of NR2F1 observed. The membrane spanning 
4 domains-subfamily A-member 1 gene, MS4A1, had the greatest fold-change; 
MS4A1 expression was 2.25-fold higher in GOLD 2/3/4 samples compared to 
GOLD 0/1.  Prior studies show that supplementation with selenomethionine 
down-regulates expression of MS4A1, thus the higher expression levels we 
observed are consistent with the hypothesis that GOLD 2/3/4 tissue is 
depleted in selenium relative to GOLD 0/1 tissue.(34) Expression of MS4A1 
was inversely associated with plasma selenium, consistent with the prior 
reports, although the correlation was not statistically significant.  
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 Strengths of this study include rigorous methods to quantify selenium 
and -tocopherol and high quality gene expression microarray data using a 
well-validated Affymetrix platform. Given the small sample size, the gene 
subset approach was an important investigative tool, particularly because our 
interest was in genes specifically related to antioxidant response and COPD. 
We examined the correlation of gene expression with tissue and plasma 
nutrient as a complementary method to test the hypothesis that genes related 
to antioxidant function are differentially expressed, and this led to supportive 
data for the contrast by COPD stage in many instances. 
 Some limitations of this study have already been noted, including the 
small sample size. Although the hypothesis-oriented genes lists for vitamin E- 
and selenium-responsive genes were developed post-hoc, which could be 
viewed as a weakness, these lists were carefully curated to identify findings for 
further confirmation. As in any study of this kind, the disease groupings must 
relate to actual differences in clinical manifestations, and the two GOLD stage 
groupings could be criticized. However, the two groups were consistently 
different on descriptive lung function data, supporting the classification used. 
Indeed, this classification also yielded the most distinct difference in lung 
tissue vitamin E levels, lending support to the hypothesis that antioxidant 
status may play a role in disease progression. An additional limitation was the 
lack of tissue to assay selenium concentrations in lung.  
 In summary, -tocopherol concentrations in lung tissue were strongly 
associated with COPD GOLD stage diagnostic level. 16 of 109 genes related 
to COPD, vitamin E- or selenium were differentially expressed by disease 
severity. Given the importance of antioxidant status in protecting the lung it is 
important to understand the relation between lung antioxidants and gene 
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expression in lung tissue as therapeutic targets may emerge from 
understanding these pathways and the interactions of antioxidant nutrients 
with individual genes. 
In conclusion, the vitamin E concentration in lung tissue of COPD 
patients was correlated with disease severity: patients with more severe 
disease had lower concentrations of vitamin E in lung tissue. A number of 
genes that are responsive to vitamin E and selenium were differentially 
expressed in lung tissue of COPD patients with moderate to very severe 
disease. Overall, these findings suggest a causal mechanism for 
epidemiologic observations that vitamin E is associated with better lung 
function and lowered risk of COPD.(31;56-58) The findings support the 
hypothesis that nutrients contribute to variation in gene regulation, and a 
further understanding of these associations may identify therapeutic value for 
vitamin E and/or selenium. 
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CHAPTER 5 
SUMMARY AND CONCLUSION 
 
Overview 
The projects completed for this dissertation were designed and 
conducted to provide a comprehensive, integrated study of chronic obstructive 
pulmonary disease (COPD). The following three projects were completed for 
this dissertation: 1) a randomized study of vitamin E supplementation and risk 
of chronic lung disease in the Women’s Health Study, which was a post hoc 
analysis of the incidence of COPD and asthma in a double-blinded 
randomized clinical trial of vitamin E and aspirin in women (referred to as 
WHS), 2) a study of the effect of supplementary antioxidant vitamins on 
plasma and airway lining fluid in cigarette smokers (referred to as ExSEL), 
which was a double-blinded randomized clinical trial investigating the effect of 
dietary antioxidant supplements in the lung compartment, and 3)  a study of 
the differential expression of vitamin E and selenium-responsive genes by 
disease severity in chronic obstructive pulmonary disease (referred to as 
LTRC), which was a small study of antioxidant concentrations in plasma and 
lung tissue in relation to gene expression in lung tissue of COPD patients at 
varying levels of disease severity. 
The WHS analyzed of the effect of randomized vitamin E 
supplementation on risk of incident chronic lung disease. In the molecular 
epidemiologic model of disease, the WHS studied exposure to vitamin E in 
relation to the COPD outcome, but without investigating biomarkers of 
antioxidant status or genetic information. The ExSEL was a small randomized 
controlled trial of the effect of antioxidant supplements on systemic and lung-
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specific concentrations of antioxidants. Thus, ExSEL linked exposure to 
nutrients with antioxidant properties to compartment-specific biomarkers of 
nutritional status and oxidative stress, but the study design precluded 
consideration of disease outcomes. The LTRC provided that last link in the 
molecular epidemiologic model by investigating biomarkers of antioxidant 
status and gene expression in relation to COPD severity, but the intake of 
nutrients with antioxidant properties was not assessed. The three projects was 
a whole were a complete study of the relation of antioxidants with COPD and 
the mediation of that relation through gene expression, which would have 
been difficult to achieve with a single study. 
The integrated nature of the three projects was deliberate. COPD is a 
complex chronic disease, and studying risk factors, pre-clinical and disease 
biomarkers, and changes in gene expression associated with disease would 
be impossible in a single study. Complex chronic diseases have a 
multifactorial etiology, and this is certainly true for COPD. In addition, COPD, 
like other complex chronic diseases, develops over a long period of time, thus 
studying time-varying exposures in relation to disease state over the full 
natural history would be challenging. Finally, COPD is a complex phenotype, 
which is thought to comprise subgroups of more homogenous 
pathophysiology, also adding to the challenges in study design. An integrated 
approach, combining several types of studies, offered the best approach to 
understanding how one aspect of diet, nutrients with antioxidant properties, 
relates to biomarkers and genetic regulation that influences COPD 
susceptibility and progression. A brief summary of the findings from each 
project is presented below followed by a short discussion of common themes 
that emerged from this work. 
106 
 
WHS Summary 
The Women’s Health Study was a randomized clinical intervention trial 
of 38,597 women health care professionals who were supplemented with 
vitamin E for 10 years. We hypothesized that supplementation with vitamin E 
decreases the occurrence rate of chronic lung disease. We performed a post 
hoc survival analysis of the WHS investigating the effect of vitamin E 
supplementation on chronic lung disease risk. During the 10-year follow-up of 
the study, vitamin E supplementation led to a 10% reduction in risk of 
developing chronic lung disease (376,710 person-years of follow-up). There 
were 760 new occurrences of chronic lung disease in the women assigned to 
the vitamin E arm of the trial compared to 846 new occurrences in women 
assigned to the placebo arm of the trial. The reduction in risk was statistically 
significant (HR 0.90; 95% CI 0.81 to 0.99). We hypothesized that smoking 
would modify the effect of the supplements, but no statistically significant 
modifiers of the effect on vitamin E supplementation on chronic lung disease 
risk were identified.  
Two prior studies investigated antioxidant supplements and COPD-
related outcomes and reported no relation of supplements to outcomes, but 
the studies were substantially different from the WHS. The Heart Protection 
Study (HPS) was 75% men and all participants had prevalent coronary artery 
disease. The Alpha-tocopherol and Beta-carotene (ATBC) study was 
comprised entirely of men, all of whom were cigarette smokers.(1;2) In these 
trials the outcomes considered included death due to respiratory illness, 
pulmonary function, and COPD-related hospitalizations. Neither trial 
considered primary prevention of COPD, nor were the studies conducted on 
women, particularly women in good general health. 
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The findings from the WHS provide important new information about the 
relation of vitamin E to chronic lung disease occurrence in women. In light of 
the prior reports of no effect in studies of male participants, this thesis 
advanced a hypothesis to account for the differential effect of vitamin E in 
women compared to men. On average, women have higher levels of high 
density lipoprotein (HDL) cholesterol; higher HDL leads are hypothesized to 
lead to greater delivery of supplemental vitamin E to the lung compartment in 
women, which would explain a greater protective effect of vitamin E in women. 
This hypothesis is based on in vitro and in vivo research showing that the 
high-density lipoproteins in the interstitial fluid deliver vitamin E to alveolar type 
II cells and that because type II cells have no contact with plasma, vitamin E 
delivery must occur through the HDLs contained in the interstitial fluid.(3;4) 
Thus, the naturally higher HDL cholesterol levels in women may allow for 
delivery of a greater biologically effective dose of vitamin E to the lung 
compartment and this difference may explain part of the sex-difference in 
findings related to vitamin E supplementation and COPD. 
This hypothesis is supported by the analysis of effect modification 
presented in Chapter 2; alcohol intake was a borderline statistically significant 
effect modifier (p=0.054) of the relation of vitamin E to COPD incidence. As 
alcohol is proposed to increase HDL (the mechanism for lowering cardiac risk 
(5;6), we speculated that stronger effects of vitamin E in moderate alcohol 
consumers may be mediated by delivery of vitamin E to lung tissue. Although 
this proposed mechanism cannot be proven with the WHS data the preventive 
effect of vitamin E in the WHS population and the effect modification by 
alcohol intake is intriguing and worthy of follow-up. The lack of effect 
modification by smoking was a surprising finding, and may offer some clues 
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about the mechanism by which vitamin E alters COPD susceptibility. One 
hypothesis is that vitamin E is acting systemically, perhaps by improving 
immune function.(7)   
There is concern about high dose vitamin E supplementation given 
potential harmful effects and these results must be interpreted with caution 
before making public health recommendations. Making recommendations for 
higher dose vitamin E supplementation in men to achieve the purported 
“effective dose” achieved by women would require substantial investigation 
with particular attention given to increased risks of stroke, bleeding, and other 
negative health outcomes. It is important to consider carefully the overall risk 
benefit profile of using dietary supplements prior to making any policy 
recommendations; furthermore, studies designed to address this question 
specifically would be needed. However, given the paucity of prevention 
strategies for chronic lung disease, the 10% reduction in risk demonstrated in 
this study is of interest and meritorious of further investigation.  
 
ExSEL Summary 
 Our study of cigarette smokers and the effect of antioxidant 
supplements on plasma and airway lining fluid, ExSEL, was a double-blind 
placebo controlled trial investigating the ability of supplementation with 
vitamins C and E and selenium to augment the lungs’ antioxidant defenses 
thereby attenuating oxidative stress imposed by smoking. We hypothesized 
that oral supplementation with antioxidants would alter lung compartment 
concentrations of those nutrients and lower a systemic marker of oxidative 
stress. We conducted a one-month clinical intervention with the dietary 
supplements in 26 study participants. Plasma and bronchioalveolar lavage 
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fluid (BALF) measurements were made to assess change in antioxidant status 
caused by the intervention. In addition, urine and plasma biomarkers of 
oxidative stress were assayed to determine whether or not the antioxidant 
altered oxidative stress caused by smoking. 
We found that antioxidant intervention increased concentrations of 
supplemented nutrients in the plasma and BALF. In response to 
supplementation, vitamin E increased 69.4% in the plasma, 67.1% in HDL, 
and 64.6% in the BALF, compared to changes in the placebo group of 21.3%, 
12.0% and -5.8%, respectively. Selenium increased 78.0% in plasma and 
46.8% in BALF due to the supplementation, while in the placebo group it 
changed -4.4% and 5.1% respectively in these fluids. These findings are 
important in establishing that the nutrients are reaching the lung compartment, 
the tissue target of the intervention. Often the assessment of whether or not an 
intervention is reaching the target tissue is overlooked in clinical trials, to the 
detriment of understanding the effectiveness of a treatment. In addition, no 
prior studies had investigated whether supplementation with antioxidants 
reached the lung compartment by directly measuring fluid from the lung, and, 
in fact, no prior work had assessed selenium in the BALF. 
The association of change in vitamin E concentrations in the plasma 
with change in the BALF was interesting. The correlation between change in 
plasma and BALF selenium was 0.57 (p = 0.0057). The correlation coefficient 
for change in plasma and BALF -tocopherol was 0.31 (p = 0.1487. Change in 
HDL and plasma -tocopherol were strongly correlated, (r = 0.60; p = 0.0024) 
suggesting that HDL vitamin E concentration is much more important in the 
transport of vitamin E to the lung. Regression models confirmed these 
findings. Additional exploration of potential to benefit investigated how starting 
110 
 
antioxidant status and level of oxidative stress affected response to 
supplementation, and while numbers were small for these analyses the 
findings were in expected directions. 
Prior to the ExSEL study, no prior studies measured plasma and lung 
concentration of antioxidants before and after intervention, and no literature 
reports of selenium in BALF were identified. Thus, the findings from ExSEL 
comprise substantial new information regarding the efficacy of nutritional 
supplements to alter lung antioxidant concentrations; these findings suggest 
preventive and therapeutic possibilities for COPD. 
 
LTRC Summary 
 The final study of my dissertation, the LTRC study, incorporates 
information about plasma and lung nutrient status and differential gene 
expression to investigate differences between disease severity groups in 
patients with COPD. We hypothesized that a lung-tissue-specific measure of 
antioxidant status would be correlated with COPD severity. We analyzed 22 
samples from patients with COPD at all 5 GOLD stages of disease severity (0-
4). Samples from 8 participants in GOLD stages 0/1 (at-risk [essentially 
disease free] and mild COPD, respectively) were compared to 16 samples 
from participants in GOLD stages 2/3/4 (moderate, severe, very severe). Lung 
tissue vitamin E concentrations decreased with increasing disease severity 
(p=0.0082). Plasma vitamin E and selenium concentrations were not 
correlated with disease severity. 
 We conducted a three-part investigation of the gene expression data, 
and all comparisons considered whether gene expression differed by GOLD 
stage group (GOLD 2-4 vs. GOLD 0-1). In the genome-wide array analysis no 
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genes were differentially expressed at genome-wide significance levels. We 
also conducted a hypothesis-oriented analysis testing four lists of genes: 
COPD susceptibility genes, genes with prior evidence of differential 
expression in COPD, genes responsive to vitamin E, and genes responsive to 
selenium. We found 16 of 109 genes investigated (across the four lists) were 
differentially expressed in GOLD 2/3/4 compared to GOLD 0-1 with FDR q-
values <0.05. Of the 16 differentially expressed genes, one was a previously 
identified COPD susceptibility gene, 3 were previously identified as 
differentially expressed in COPD, six were related to vitamin E, and six were 
related to selenium. 
 Differentially expressed genes were analyzed further for associations 
between antioxidant status and gene expression. Four genes were found to 
have expression significantly correlated with one or more antioxidant 
biomarkers. Of these genes peroxisome proliferator-activated receptor 
gamma, PPARG, was particularly interesting because it had been previously 
identified to be responsive to vitamin E and was associated with plasma 
vitamin E concentrations. Earlier reports of the regulatory effect of vitamin E 
on PPARG indicate that the gene is upregulated in response to vitamin E.(8) 
In our samples lung tissue from patients with more severe disease contained 
less vitamin E and this was associated with lower levels of PPARG gene 
expression. 
 Our findings support the hypothesis that lung nutrient status is lower in 
patients with more severe disease and that the differential expression of genes 
in lung tissue is associated with variation in tissue and plasma levels of 
antioxidant nutrients. These findings suggest a causal mechanism for 
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epidemiologic reports of COPD prevention via antioxidants and support the 
idea that targeted nutritional inventions may have therapeutic value. 
 
Emerging Themes and Future Directions 
 Several common themes emerged from the three studies conducted for 
my dissertation research. First, supplementation with antioxidants may provide 
a useful COPD prevention, but the effect may differ by sex. The sex-based 
effect of vitamin E on disease prevention seen in the WHS gained additional 
support from the findings from ExSEL. Firstly, in ExSEL we found that the 
change in HDL vitamin E was more predictive of change in lung vitamin E than 
was overall change in plasma vitamin E. The importance of HDL cholesterol in 
delivery of vitamin E to the lung and the proposed link between HDL and the 
differential effect by sex is interesting and novel. 
 Differential expression in lung tissue of genes related not only to COPD 
but also to antioxidants provides additional support for our hypothesis that 
nutritional status is an important part of the disease process in COPD. 
Identification of PPARG as a differentially expressed gene in GOLD 2/3/4 
compared to GOLD 0/1 was very interesting because it has been shown to be 
upregulated in response to vitamin E.(8) Furthermore, PPARs have been 
shown to be involved in lipid biosynthesis and glucose metabolism and they 
have some anti-inflammatory and immunomodulatory properties mediated 
through down regulation of pro-inflammatory genes.(9) For this reason, 
PPARs have recently been proposed as therapeutic targets in inflammatory 
lung disease, with the goal being to upregulate these genes to enhance their 
anti-inflammatory properties.(9) Our work from the LTRC study provides 
preliminary evidence that vitamin E could act as an expression modifier of 
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PPARG. A supporting line of evidence, from unpublished data in the ExSEL 
study, shows that PPARG is upregulated in epithelial cells of participants 
taking active vitamin E supplements compared to participants on placebos. 
While these data require fuller analysis, the finding is intriguing and provides 
interesting directions for exploring possible therapeutic and preventive roles 
for vitamin E in relation to COPD. Pharmacologic investigations of PPARG 
agonist drugs, such as rosiglitazone for asthma, are underway.(9) 
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APPENDIX 
 
Supplemental Methods A.1 
Detailed Assay Methods 
HPLC Determination of Plasma Vitamin C 
Preservation of plasma samples for vitamin C determination by HPLC 
To preserve the ascorbic acid, a 0.7 ml aliquot of plasma was added to 
a cryogenic vial containing 0.7 ml of pre-cooled 10% meta-phosphoric acid 
(MPA) solution then immediately frozen at -80ºC.  
HPLC determination of plasma vitamin C 
Upon thawing, samples were mixed and centrifuged at 4ºC, 10,000 rpm 
for 5 min. A 50 l portion of supernatant was mixed with 150 l dipotassium 
phosphate containing tris[2-carboxyethyl]phosphine hydrochloride (TCEP) to 
reduce any dehydroascorbic acid to ascorbic acid. Samples were incubated 1 
hour at room temp. Next samples were acidified with 50 l 40% MPA and 50 
l of hypoxanthine, added as internal standard, and mixed prior to transferring 
to autosampler vials. Twenty microliters was injected for analysis by HPLC. A 
Synergi Hydro RP, 250 x 4.6 mm, 4 m column was used with UV detection at 
245 nm (5 cm light-pipe flowcell), EC 200 mV, 10 nA. The mobile phase was 
2% methanol in 25 mM monochloroacetic acid, 2 mM EDTA, pH 3.0. The flow 
rate was 0.8 ml/min with column temperature of 32ºC and sample temperature 
of 15ºC.  
Three known-value serum standards (0.41 g/ml ± 11.1%, 1.94 g/ml ± 
2.66%, and 14.1 g/ml ± 1.63%) were concurrently measured in duplicate to 
assess assay precision. The average percent standard deviation was 5.14% 
for the six measurements of the three standards.  
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Vitamin C measurements were completed by Craft Technologies, 
Wilson, NC. 
 
Gas Chromatography Mass Spectrometry (GC-MS) Determination of -
tocopherol 
No special sample preservation methods were required for vitamin E 
assays.  
Plasma total -tocopherol sample preparation 
Briefly, 3 l of a 9- -tocopherol internal standard (99 mol/L stock 
solution) was added to 75 l of plasma. 150 l of ethanol was added, then 
vortexed. To extract lipids 75 l of methyl-tert-butylether and 1.0 ml hexane 
were added and sample was shaken for 2 minutes. Samples were centrifuged 
at 15,000 rpm for 1 minute then the upper hexane phase was transferred to a 
small vial. The hexane was evaporated to dryness under a nitrogen stream 
and in a 30ºC water bath. The residues were silylated in 40 l pyridine 
(Thermo Scientific) and 40 l N,O-bis[trimethylsilyl]trifluoroacetimide (Thermo 
Scientific). The headspace was flushed with nitrogen then samples were 
tightly capped and placed in a 75ºC dry oven for 25 minutes. 
Plasma HDL cholesterol -tocopherol sample preparation 
20 l of HDL cholesterol precipitating reagent (Stanbio) was added to 
150 l of plasma and allowed to stand for 5 minutes, then centrifuged at 
15,000 rpm for 1 minute. 75 l of supernatant was transferred to a tube; then 
the procedure for plasma total -tocopherol was followed. 
Bronchioalveolar lavage fluid -tocopherol sample preparation 
3 l of a 9-tocopherol internal standard (99 mol/L stock solution) was 
added to 4 ml of BAL fluid. 10 ml of a 90:10 hexane/methyl-tert-butylether and 
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30 l of butylhydroxytoluene solution (10 mmol/L in 90:10 hexane/MTBE) was 
added to the tube, covered with nitrogen then tightly capped and shaken for 
two minutes. Samples were centrifuged for 5 minutes at 1000 rpm. The 
hexane phase was removed to a new tube, evaporated to 1-2 ml volume 
under a nitrogen stream and in a 30ºC water bath. The reduced volume was 
transferred to a small vial, evaporated to dryness under nitrogen in the water 
bath. The residue was silylated in 40 l pyridine (Thermo Scientific) and 40 l 
N,O-bis[trimethylsilyl]trifluoroacetimide (Thermo Scientific). The headspace 
was flushed with nitrogen then samples were tightly capped and placed in a 
75ºC dry over for 25 minutes. 
GC-MS determination of tocopherols 
-Tocopherol concentrations in plasma (total and HDL) and 
bronchioalveolar lavage fluid samples were determined by GC-MS, using a 
Hewlett Packard 6890 gas chromatograph coupled to a Hewlett Packard 6890 
mass spectrometer. Tocopherols were resolved isothermally at 280ºC on an 
HP-1 capillary column (Agilent Technologies) operated in split injection mode 
with helium as the carrier gas. Detection was by selected ion monitoring (SIM 
mode). Tocopherol and free cholesterol (as silyl ethers) were quantitated 
against the 9- -tocopherol internal standard, adjusting the cholesterol values 
for predetermined differences in detector response.  
Samples were assayed in duplicate and average coefficients of 
variation were determined for total -tocopherol and for cholesterol-adjusted 
total -tocopherol (where cholesterol was measured within the GC-MS 
method), respectively, with values as follows: plasma total -tocopherol (4.2% 
and 2.4%), plasma HDL cholesterol -tocopherol (13.2% and 4.0%), and 
bronchioalveloar lavage fluid -tocopherol (11.6% and 6.2%). 
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 Vitamin E assays were completed in the Division of Nutritional 
Sciences, Cornell University, Ithaca, NY. 
 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Determination 
of Selenium 
No special sample preservation methods were required for selenium 
assays. 
Plasma selenium sample preparation 
A 2% nitric acid solution was prepared using concentrated nitric acid 
from a Teflon sub-boiling still and double-deionized water, resistivity > 18 M  
cm. Plasma samples were prepared for selenium analysis by adding 5 ml of 
2% HNO3 to 100 l of plasma (thawed at room temperature). Two reference 
standard solutions, 1 ppb and 5 ppb, were run at regular intervals throughout 
sample testing and average concentrations were determined to be 1.002 ppb 
and 5.117 ppb, respectively with standard deviations of 0.023 and 0.073, 
respectively. Seronorm Trace Elements, Serum, Levels I and II (Accurate 
Chemical & Scientific Corp., Westbury, NY) and two NBS standard samples 
were used as reference materials for method validation and assessment of 
accuracy and precision. Seronorm and NBS samples were prepared in the 
same way as the plasma samples and run at regular intervals throughout 
sample testing. All four reference materials were determined to have values 
within the range of acceptable results for the material.  
Bronchioalveolar lavage fluid selenium sample preparation 
BALF samples were prepared for selenium analysis by adding 0.5 ml of 
BALF to a small vial then evaporating to dryness under a nitrogen stream and 
in a 30ºC water bath. Immediately prior to analysis the samples were 
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reconstituted in 50 l of 2% HNO3 spiked with 1 ppb germanium (Ge) as an 
internal standard. A reference solution containing 1 ppb of Ge and Se in 2% 
HNO3 was analyzed at regular intervals throughout sample testing. The BALF 
was primarily composed of saline solution and the sodium contained within the 
BALF samples interfered with detector response to Ge and Se ions. 
Interference was quantitated and adjusted for by assessing Ge and Se 
response in the reference solution and comparing it to the reduced response 
in the samples that were reconstituted in the Ge-spiked solution. 
ICP-MS determination of total plasma and BALF selenium 
An Agilent 7500 cs/ce quadrupole ICP-MS equipped with a collision 
reaction cell was used to determine selenium concentration in plasma 
samples. The ion intensity at m/z 78 was used to monitor Se and 89Y was 
used as an internal standard for plasma samples and 72Ge for BALF samples. 
For plasma samples data were collected using the Spectrum mode for direct 
analysis. For BALF samples data were collected using the transient mode. 
Maximum sensitivity was obtained by daily tuning of the ion lens system, gas 
flow rates, and other parameters. Samples were run manually with continuous 
quality monitoring. Table A.1 summarizes the operating conditions and 
instrumental parameters.  
Sample preparation and analysis was performed at the USDA Plant, 
Soil, & Nutrition Laboratory, Cornell University, Ithaca, NY. 
 
  
121 
 
Table A.1 Inductively Coupled Mass Spectrometry (ICP-MS) operating 
conditions and instrumental parameters for plasma and BALF selenium 
determination* 
 
RF power 1400 Watts 
Sample uptake rate 2.5 ml/min 
Reaction mode He or H2, 5 ml/min, Spectrum mode 
Gas flow rates:  
Plasma gas Ar,  
Auxillary gas 0 L/min 
Carrier gas Plasma: Ar, 0.8 L/min 
BALF: Ar, 0.45 L/min 
Makeup gas Plasma: Ar, 0.45 L/min 
BALF: Ar, 0.75 L/min 
Ion sampling depth 8 mm 
Torch Quartz 2.5 mm id fitted with Agilent ShieldTorch system 
Nebulizer Microliter nebulizer, Microglass (Cedar Ridge, CO) 
Sample cone Pt, orifice diameter 1.0 mm 
Skimmer cone Pt, orifice diameter 0.4 mm 
Spray chamber Double cyclonic and water cooled Scott type 
Integration time Plasma: 0.2000 sec 
BALF: 0.1000 sec/point 
Sampling period Plasma: 0.6000 sec 
BALF: 20.0 sec 
Sweeps per reading Plasma: 40-60 
BALF: Transient 
*Unless otherwise noted, the conditions and parameters for plasma and BALF samples were 
the same. 
 
Mass Spectrometry Determination of F2-Isoprostanes in Plasma
 
Purification and preparation of plasma samples 
For analysis, to 1-3 ml of plasma was added 1.0 ng of [2H4]-15-F2t-IsoP 
([2H4]-8-iso-PGF2a; Cayman Chemical, Ann Arbor, MI) internal standard. The 
solution was adjusted to pH 3 with 1N HCl. The sample was then applied to a 
C-18 Sep-Pak cartridge that has been prewashed with 5 ml methanol and 5 ml 
0.01N HCl. The cartridge was then washed with 10 ml 0.01N HCl, followed by 
10 ml heptane, and compounds are then eluted with 10 ml ethyl 
acetate:heptane (50:50, v/v). The eluate was applied to a silica Sep-Pak 
cartridge prewashed with ethyl acetate (5 ml). It was rinsed with 5 ml ethyl 
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acetate and compounds eluted with 5 ml ethyl acetate:methanol (50:50, v/v). 
The eluate was dried under nitrogen. Compounds were converted to the 
pentafluorobenzyl (PFB) esters by the addition of 40 μl of a 10% solution of 
pentafluorobenzyl bromide in acetonitrile and 20 μl of a solution of 10% 
diisopropylethanolamine in acetonitrile and allowed to incubate for 30 minutes 
at 37ºC. Reagents were dried under nitrogen and the residue reconstituted in 
30 μl chloroform and 20 μl methanol and chromatographed on a silica TLC 
plate to 13 cm in a solvent system of chloroform:methanol (93:7, v/v). The 
methyl ester of PGF2α was chromatographed on a separate lane and 
visualized with 10% phosphomolybdic acid in ethanol by heating. The Rf of 
PGF2α methyl ester in this solvent system was 0.15. Compounds migrating in 
the region 1 cm below the PGF2α standard to 1.0 cm above the standard were 
scraped from the TLC plate, extracted with 1 ml ethyl acetate, and dried under 
nitrogen. Following TLC purification, compounds were converted to 
trimethylsilyl (TMS) ether derivatives by addition of 20 μl N,O-
bis(trimethylsilyl)trifluoroacetamide and 10 μl dimethylformamide. The sample 
was incubated at 37ºC for 10 minutes and then dried under nitrogen. The 
residue was re-dissolved for GC/MS analysis in 20 μl undecane that was 
stored over a bed of calcium hydride. 
Mass spectrometry detection of plasma F2-isoprostanes 
Gas chromatography-negative-ion chemical ionization mass 
spectrometry (GC/NICI-MS) was carried out on an Agilent 5973 Inert Mass 
Selective Detector coupled with an Agilent 6890n Network GC system (Agilent 
Labs, Torrance, CA) interfaced with an Agilent computer. GC was performed 
using a 15 m, 0.25 m film thickness, DB-1701 fused silica capillary column (J 
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and W Scientific, Folsom CA). The column temperature was programmed from 
190º to 300ºC at 20ºC per minute.  
The major ion generated in the NICI mass spectrum of the PFB ester, TMS 
ether derivative of F2-IsoPs was the m/z 569 carboxylate anion [M-181 (M-
CH2C6F5)]. The corresponding ion generated by the [
2H4]-15-F2t-IsoP internal 
standard was m/z 573. Levels of endogenous F2-IsoPs in a biological sample 
were calculated from the ratio of intensities of the ions m/z 569 to m/z 573. 
The lower limit of detection of F2-IsoPs was in the range of 4 pg using an 
internal standard with a blank of 3 parts per thousand. The precision of this 
assay in biological fluids is +6% and the accuracy 94%. 
F2-isoprostane measurements were performed by the Eicosanoid Core 
Laboratory, Vanderbilt University Medical Center, Nashville, TN. 
 
Determination of F2-isoprostanes in Urine Samples 
Purification of urine samples 
Urine was collected using a “clean catch” method into sterile urine 
collection containers. Urine samples were pipetted into cryovials in 2 ml 
aliquots then immediately frozen at -80oC. Samples were thawed at room 
temperature, centrifuged to remove particulates, then 1 ml aliquots were 
added to microcentrifuge tubes. Addition of 200 l of sorbent to the 
microcentrifuge tubes was followed by gentle mixing for 45 minutes. The tubes 
were then centrifuged to sediment out the sorbent and the supernatant was 
removed and disposed of. The remaining sorbent was washed with 1 ml 
Nanopure water then centrifuged with removal and disposal of the 
supernatant. The washing procedure was repeated. The washed sorbent was 
then resuspended in 0.5 ml 95% ethanol (elution buffer) (Fisher Scientific) and 
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briefly vortexed. The sample was then centrifuged and the elution buffer was 
removed and saved. The resuspension was repeated and the elution buffer 
washes were all combined and dried down overnight on a speed vacuum. 
Dried samples were then dissolved in 1 ml of EIA buffer (Cayman Chemicals). 
 Enzyme linked immunoassay measurement of F2-isoprostanes 
F2-isoprostanes in urine samples were measured using a competitive 
enzyme linked immunoassay (ELISA) kit from Cayman Chemicals (Ann Arbor, 
MI). Dilute EIA and wash buffers were prepared with Nanopure water, per the 
kit instructions. Eight standard samples were prepared by mixing with EIA 
buffer with the standard using serial dilutions. The tracer was reconstituted 
with 6 ml of EIA buffer and the antiserum was reconstituted with 6 ml of EIA 
buffer. 
Plate set up was performed per the Cayman Chemical suggested 
method, which included at least two different dilutions of each sample. After all 
standards, samples, tracers and antiserum aliquots were added to the plate, 
the plate was covered and incubated for 18 hours at 4ºC. The plate was 
developed by reconstituting 250 dtn of Ellman’s Reagent with 20 ml of 
Nanopure water. The plate was washed 5X with wash buffer solution. To each 
well of the plate, 200 l of Ellman’s Reagent was added and 5 l of tracer was 
added to total activity wells. The plate was then covered and the plates were 
developed on a shaker in the dark. The plate was read at 405 nm wavelength 
after 60 minutes and 90 minutes of development. 
Control samples were run on each plate and the overall coefficient of 
variation was determined to be 18.7%. Additionally, standard curve correlation 
values were determined at two time points and the average R2 value was 
0.9911 at each time point with average R2 standard deviation of 0.0040. 
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Measurement of urine creatinine 
Creatinine was measured on a Siemens Dimension Xpand Plus, a 
Centers for Disease Control and Prevention certified instrument, using 
standard methods recommended by the manufacturer. 
 
Chemiluminescence Determination of Plasma Cholesterols and 
Triglycerides 
Total, HDL, and LDL cholesterol and triglycerides were determined 
using chemiluminescence under standard methods on a Siemens Dimension 
Xpand, a Centers for Disease Control and Prevention certified instrument. 
Average within run and between run coefficients of variation for the analytes 
were, respectively, total cholesterol (0.71% and 1.94%), HDL cholesterol 
(0.36% and 4.20%), LDL cholesterol (0.48% and 3.10%), and triglycerides 
(0.28% and 2.12%). Two control samples, Biorad Liquid Assayed Multiqual 
Level 1 and Level 3, were assayed and all values for the lipids were 
determined to be within the acceptable range. 
Urinary F2-isoprostane, creatinine, cholesterol and triglyceride 
measurements were performed in the Francis Johnston and Charlotte Young 
Human Metabolic Research Unit, Cornell University, Ithaca, NY. 
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Figure A.1 Principal component analysis (PCA) of plasma nutrient levels of 
ExSEL participants; two participants assigned to the active supplement arm 
(yellow markers) were deemed “non-compliant” based on PCA grouping with 
the participants assigned to the placebo arm of the study. 
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Table A.2 Gene lists developed by literature review for genes identified in 
genome-wide association studies (GWAS) of COPD, gene expression studies 
of COPD, and studies of vitamin E and selenium-responsive genes 
Gene Name Entrez ID Description 
A.2.a. COPD GWAS gene list; N = 6 
BICD1 2671 bicaudal D homolog 1 (Drosophila) 
CHRNA3 5927 cholinergic receptor, nicotinic, alpha 3 
CHRNA5 11108 cholinergic receptor, nicotinic, alpha 5 
FAM13A 17489 family with sequence similarity 13, member A 
HHIP 5024 hedgehog interacting protein 
SERPINE2 5270 serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 2 
A.2.b. COPD differential expression gene list; N = 22 
ADAM33 80332 ADAM metallopeptidase domain 33 
CAT 847 catalase 
COL1A1 1277 collagen, type I, alpha 1 
COL3A1 1281 collagen, type III, alpha 1 
EGR1 1958 early growth response 1 
FN1 2335 fibronectin 1 
GSTP1 2950 glutathione S-transferase pi 1 
IL13 3596 interleukin 13 
IL1B 3553 interleukin 1, beta 
IL8 3576 interleukin 8 
MMP10 4319 matrix metallopeptidase 10 (stromelysin 2) 
MMP2 4313 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 
72kDa type IV collagenase) 
MMP9 4318 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
PLAU 5328 plasminogen activator, urokinase 
PLAUR 5329 plasminogen activator, urokinase receptor 
SERPINE2 5270 serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 2 
TGFB3 7043 transforming growth factor, beta 3 
TIMP1 7076 TIMP metallopeptidase inhibitor 1 
TIMP2 7077 TIMP metallopeptidase inhibitor 2 
TNF 7124 tumor necrosis factor 
VEGFA 7422 vascular endothelial growth factor A 
VEGFB 7423 vascular endothelial growth factor B 
A.2.c. Vitamin E responsive gene list; N = 42 
ACTA1 7227 actin, alpha 1, skeletal muscle 
ALOX12 7198 arachidonate 12-lipoxygenase 
ALOX5 3473 arachidonate 5-lipoxygenase 
CD36 16861 CD36 molecule (thrombospondin receptor) 
CEBPG 3904 CCAAT/enhancer binding protein (C/EBP), gamma 
COL1A1 1277 collagen, type I, alpha 1 
CTGF 7738 connective tissue growth factor 
CYP1A1 8315 cytochrome P450, family 1, subfamily A, polypeptide 1 
CYP2A13 5312 cytochrome P450, family 2, subfamily A, polypeptide 13 
CYP3A4 13090 cytochrome P450, family 3, subfamily A, polypeptide 4 
CYP4F2 6541 cytochrome P450, family 4, subfamily F, polypeptide 2 
CYP7B1 5894 cytochrome P450, family 7, subfamily B, polypeptide 1 
GFI1 3508 growth factor independent 1 transcription repressor 
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Table A.2 Gene lists developed by literature review for genes identified in 
genome-wide association studies (GWAS) of COPD, gene expression studies 
of COPD, and studies of vitamin E and selenium-responsive genes 
(Continued) 
Gene Name Entrez ID Description 
A.2.c. Vitamin E responsive gene list; N = 42 (continued) 
GP2 17066 glycoprotein 2 (zymogen granule membrane) 
GSTM3 11498 glutathione S-transferase mu 3 (brain) 
HMGCR 7930 3-hydroxy-3-methylglutaryl-CoA reductase 
HMGCS2 7851 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 
IGF1 15830 insulin-like growth factor 1 (somatomedin C) 
IL17D 4115 interleukin 17D 
IL3 6311 interleukin 3 (colony-stimulating factor, multiple) 
KRT1 2469 keratin 1 
KRT13 11968 keratin 13 
KRT15 8523 keratin 15 
KRT4 2999 keratin 4 
KRT7 3709 keratin 7 
LPL 7891 lipoprotein lipase 
MMP1 10851 matrix metallopeptidase 1 (interstitial collagenase) 
MMP19 3598 matrix metallopeptidase 19 
MYH1 6344 myosin, heavy chain 1, skeletal muscle, adult 
NOX3 5315 NADPH oxidase 3 
NOX5 5470 NADPH oxidase, EF-hand calcium binding domain 5 
PGD 3980 phosphogluconate dehydrogenase 
POR 6508 P450 (cytochrome) oxidoreductase 
PPARG 2477 peroxisome proliferator-activated receptor gamma 
SRA1 2473 steroid receptor RNA activator 1 
SRD5A1 8341 steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-
steroid delta 4-dehydrogenase alpha 1) 
SULT2B1 2718 sulfotransferase family, cytosolic, 2B, member 1 
TNF 7124 tumor necrosis factor 
TNNI2 2067 troponin I type 2 (skeletal, fast) 
TPM1 8667 tropomyosin 1 (alpha) 
TPM2 6127 tropomyosin 2 (beta) 
TTPA 19077 tocopherol (alpha) transfer protein 
A.2.d. Selenium responsive gene list; N = 42 
CDH5 3236 cadherin 5, type 2 (vascular endothelium) 
DPYSL2 3902 dihydropyrimidinase-like 2 
ELF3 10820 E74-like factor 3 (ets domain transcription factor, epithelial-
specific ) 
FOSL1 4385 FOS-like antigen 1 
FOXC1 19967 forkhead box C1 
G6PD 5681 glucose-6-phosphate dehydrogenase 
GLRX 4654 glutaredoxin (thioltransferase) 
GNGT2 2145 guanine nucleotide binding protein (G protein), gamma 
transducing activity polypeptide 2 
GPX1 9761 glutathione peroxidase 1 
GPX2 4135 glutathione peroxidase 2 (gastrointestinal) 
GPX3 6707 glutathione peroxidase 3 (plasma) 
GPX4 10100 glutathione peroxidase 4 (phospholipid hydroperoxidase) 
GPX7 5452 glutathione peroxidase 7 
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Table A.2 Gene lists developed by literature review for genes identified in 
genome-wide association studies (GWAS) of COPD, gene expression studies 
of COPD, and studies of vitamin E and selenium-responsive genes 
(Continued) 
Gene Name Entrez ID Description 
A.2.d. Selenium responsive gene list; N = 42 (continued) 
GRIK1 16028 glutamate receptor, ionotropic, kainate 1 
GRIK3 6560 glutamate receptor, ionotropic, kainate 3 
GSR 19141 glutathione reductase 
GSS 19906 glutathione synthetase 
GSTA1 17259 glutathione S-transferase alpha 1 
GSTK1 16237 glutathione S-transferase kappa 1 
GSTO1 2178 glutathione S-transferase omega 1 
HOMER3 3089 homer homolog 3 (Drosophila) 
IGF1R 3620 insulin-like growth factor 1 receptor 
MGST1 12928 microsomal glutathione S-transferase 1 
MS4A1 2109 membrane-spanning 4-domains, subfamily A, member 1 
NR2F1 1914 nuclear receptor subfamily 2, group F, member 1 
NR4A2 17279 nuclear receptor subfamily 4, group A, member 2 
NR5A1 14212 nuclear receptor subfamily 5, group A, member 1 
P4HA1 2076 prolyl 4-hydroxylase, alpha polypeptide I 
PTGER2 3333 prostaglandin E receptor 2 (subtype EP2), 53kDa 
PXN 7128 paxillin 
SELK 3643 selenoprotein K 
SELP 5264 selectin P (granule membrane protein 140kDa, antigen CD62) 
SELT 1950 selenoprotein T 
SEPHS1 5618 selenophosphate synthetase 1 
SEPP1 9702 selenoprotein P, plasma, 1 
SEPW1 16285 selenoprotein W, 1 
SNAP23 11915 synaptosomal-associated protein, 23kDa 
SORT1 4920 sortilin 1 
TGFA 3468 transforming growth factor, alpha 
TXN 7142 thioredoxin 
TXNRD1 5684 thioredoxin reductase 1 
TXNRD2 10329 thioredoxin reductase 2 
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Table A.3 Genome-wide microarray results; the 25 genes of highest statistical 
significance in analysis of differential expression in GOLD Stage 2/3/4 lung 
tissue compared to GOLD 0/1 lung tissue 
 
Gene Symbol Gene name Fold change* Raw p-value FDR q-value 
C9orf30 
chromosome 9 open reading 
frame 30 -1.40151 0.000144 0.266832 
CHRAC1 
chromatin accessibility 
complex 1 -1.25305 0.000156 0.266832 
CXCL12 
chemokine (C-X-C motif) 
ligand 12 1.6757 0.000156 0.266832 
DSC2 desmocollin 2 -1.39102 9.11E-05 0.266832 
GMFB glia maturation factor, beta -1.37378 2.05E-05 0.266832 
HOXA6 homeobox A6 1.245532 6.46E-05 0.266832 
ING2 
inhibitor of growth family, 
member 2 -1.57695 0.000109 0.266832 
LOC100289494 
hypothetical protein 
LOC100289494 -1.36152 4.49E-05 0.266832 
OPN3 opsin 3 -1.42583 0.00014 0.266832 
NR2F1 
nuclear receptor subfamily 
2, group F, member 1 1.541015 0.002575 0.378227 
SELT selenoprotein T -1.17592 0.003286 0.378227 
A2M alpha-2-macroglobulin 1.245199 0.00182 0.378227 
ABHD13 
abhydrolase domain 
containing 13 -1.25626 0.001518 0.378227 
ACYP2 
acylphosphatase 2, muscle 
type -1.20728 0.002389 0.378227 
ANXA2P3 annexin A2 pseudogene 3 -1.23764 0.001282 0.378227 
ARAP2 
ArfGAP with RhoGAP 
domain, ankyrin repeat and 
PH domain 2 -1.37831 0.000618 0.378227 
ARL13B 
ADP-ribosylation factor-like 
13B -1.41753 0.00099 0.378227 
ARPP19 
cAMP-regulated 
phosphoprotein, 19kDa -1.17859 0.003087 0.378227 
ATP6V1G1 
ATPase, H+ transporting, 
lysosomal 13kDa, V1 
subunit G1 -1.14135 0.003383 0.378227 
BHLHE41 
basic helix-loop-helix family, 
member e41 -1.34452 0.002968 0.378227 
BPNT1 
3'(2'), 5'-bisphosphate 
nucleotidase 1 -1.26504 0.002316 0.378227 
BRD8 bromodomain containing 8 1.176533 0.003433 0.378227 
BRP44L brain protein 44-like -1.18758 0.000572 0.378227 
BTG1 
B-cell translocation gene 1, 
anti-proliferative 1.212408 0.001581 0.378227 
BTN2A1 butyrophilin, subfamily 2, 
member A1 1.195579 0.001928 0.378227 
*Log2 fold change
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Table A.4 COPD GWAS gene list results of analysis of differential expression 
in GOLD Stage 2/3/4 lung tissue compared to GOLD 0/1 lung tissue 
 
Gene Symbol Gene name Fold change* Raw p-value FDR q-value
†
 
BICD1 
bicaudal D homolog 1 
(Drosophila) 1.210257 0.024929 0.0251 
HHIP hedgehog interacting protein -1.32122 0.117633 0.0403 
SERPINE2 
serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 2 1.437754 0.139622 0.0403 
CHRNA3 
cholinergic receptor, 
nicotinic, alpha 3 -1.05504 0.159834 0.0403 
CHRNA5 
cholinergic receptor, 
nicotinic, alpha 5 -1.03956 0.443572 0.0894 
FAM13A 
family with sequence 
similarity 13, member A 1.027545 0.838441 0.1408 
*Log2 fold change 
†
Estimated for gene list individually 
 
 
Table A.5 COPD expression gene list results of analysis of differential 
expression in GOLD Stage 2/3/4 lung tissue compared to GOLD 0/1 lung 
tissue 
 
Gene Symbol Gene name Fold change* Raw p-value FDR q-value
†
 
PLAUR 
plasminogen activator, 
urokinase receptor -1.88258 0.014997 0.0426 
VEGFB 
vascular endothelial growth 
factor B -1.25792 0.025445 0.0426 
MMP2 
matrix metallopeptidase 2 
(gelatinase A, 72kDa 
gelatinase, 72kDa type IV 
collagenase) 1.519434 0.034261 0.0426 
CAT catalase -1.21559 0.073803 0.0653 
VEGFA 
vascular endothelial growth 
factor A -1.22743 0.107217 
0.0653 
TIMP1 
TIMP metallopeptidase 
inhibitor 1 1.346775 0.12917 
0.0653 
SERPINE2 
serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 2 1.437754 0.139622 
0.0653 
COL1A1 collagen, type I, alpha 1 1.492563 0.140078 0.0653 
MMP9 
matrix metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 1.801175 0.189926 0.0738 
TNF tumor necrosis factor 1.132183 0.198166 0.0738 
MMP10 
matrix metallopeptidase 10 
(stromelysin 2) 1.204124 0.217626 0.0738 
ADAM33 
ADAM metallopeptidase 
domain 33 1.074191 0.269388 0.0834 
COL3A1 collagen, type III, alpha 1 1.37664 0.290469 0.0834 
FN1 fibronectin 1 1.070624 0.373036 0.0877 
EGR1 early growth response 1 1.548171 0.379473 0.0877 
IL8 interleukin 8 -1.67248 0.401375 0.0877 
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Table A.5 COPD expression gene list results of analysis of differential 
expression in GOLD Stage 2/3/4 lung tissue compared to GOLD 0/1 lung 
tissue (continued) 
Gene Symbol Gene name Fold change* Raw p-value FDR q-value
†
 
TGFB3 
transforming growth factor, 
beta 3 1.125656 0.403536 
0.0877 
IL13 interleukin 13 -1.0517 0.42577 0.0877 
PLAU 
plasminogen activator, 
urokinase -1.15553 0.446406 
0.0877 
TIMP2 
TIMP metallopeptidase 
inhibitor 2 -1.03375 0.662188 0.1235 
IL1B interleukin 1, beta -1.06185 0.87487 0.1516 
GSTP1 glutathione S-transferase pi 1 1.008482 0.894088 0.1516 
*Log2 fold change 
†
Estimated for gene list individually 
 
 
 
Table A.6 Vitamin E-responsive gene list results of analysis of differential 
expression in GOLD Stage 2/3/4 lung tissue compared to GOLD 0/1 lung 
tissue 
 
Gene Symbol Gene name Fold change* Raw p-value FDR q-value† 
TNNI2 troponin I type 2 (skeletal, fast) -1.34288 0.006746 0.0241 
KRT1 keratin 1 1.513615 0.018596 0.0241 
SRA1 
steroid receptor RNA activator 
1 -1.15596 0.018731 0.0241 
PPARG 
peroxisome proliferator-
activated receptor gamma -1.76395 0.018851 0.0241 
SULT2B1 
sulfotransferase family, 
cytosolic, 2B, member 1 -1.42175 0.026493 0.0271 
KRT4 keratin 4 -2.29597 0.035531 0.0303 
ALOX5 arachidonate 5-lipoxygenase -1.3354 0.052753 0.0306 
GFI1 
growth factor independent 1 
transcription repressor 1.118384 0.054023 0.0306 
MMP19 matrix metallopeptidase 19 -1.67281 0.057065 0.0306 
KRT7 keratin 7 1.385154 0.06216 0.0306 
CEBPG 
CCAAT/enhancer binding 
protein (C/EBP), gamma -1.13516 0.070046 0.0306 
PGD 
phosphogluconate 
dehydrogenase -1.29376 0.072839 0.0306 
IL17D interleukin 17D -1.41034 0.077823 0.0306 
CYP2A13 
cytochrome P450, family 2, 
subfamily A, polypeptide 13 1.105373 0.13142 0.0421 
NOX3 NADPH oxidase 3 -1.08219 0.131562 0.0421 
NOX5 
NADPH oxidase, EF-hand 
calcium binding domain 5 -1.06578 0.139037 0.0421 
COL1A1 collagen, type I, alpha 1 1.492563 0.140078 0.0421 
CYP7B1 
cytochrome P450, family 7, 
subfamily B, polypeptide 1 -1.10751 0.158604 0.0422 
TPM2 tropomyosin 2 (beta) 1.212658 0.169813 0.0422 
IL3 
interleukin 3 (colony-
stimulating factor, multiple) -1.07219 0.178549 0.0422 
MYH1 
myosin, heavy chain 1, 
skeletal muscle, adult 1.397803 0.180132 0.0422 
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Table A.6 Vitamin E-responsive gene list results of analysis of differential 
expression in GOLD Stage 2/3/4 lung tissue compared to GOLD 0/1 lung 
tissue (continued) 
 
Gene Symbol Gene name Fold change* Raw p-value FDR q-value† 
POR 
P450 (cytochrome) 
oxidoreductase -1.17823 0.187581 0.0422 
CYP4F2 
cytochrome P450, family 4, 
subfamily F, polypeptide 2 -1.08543 0.189601 0.0422 
TNF tumor necrosis factor 1.132183 0.198166 0.0422 
ALOX12 arachidonate 12-lipoxygenase -1.06314 0.224057 0.0444 
ACTA1 actin, alpha 1, skeletal muscle -1.0717 0.225743 0.0444 
CTGF connective tissue growth factor 1.340231 0.252021 0.0449 
HMGCS2 
3-hydroxy-3-methylglutaryl-
CoA synthase 2 
(mitochondrial) -1.42727 0.258687 0.0449 
LPL lipoprotein lipase -1.14447 0.260949 0.0449 
HMGCR 
3-hydroxy-3-methylglutaryl-
CoA reductase -1.1864 0.263609 0.0449 
CYP1A1 
cytochrome P450, family 1, 
subfamily A, polypeptide 1 -1.0573 0.28408 0.0453 
SRD5A1 
steroid-5-alpha-reductase, 
alpha polypeptide 1 (3-oxo-5 
alpha-steroid delta 4-
dehydrogenase alpha 1) 1.100896 0.284933 0.0453 
KRT15 keratin 15 1.313472 0.294143 0.0453 
TPM1 tropomyosin 1 (alpha) 1.143493 0.301014 0.0453 
MMP1 
matrix metallopeptidase 1 
(interstitial collagenase) 1.492249 0.428372 0.0626 
GSTM3 
glutathione S-transferase mu 3 
(brain) -1.16204 0.468294 0.0665 
KRT13 keratin 13 -1.03788 0.495784 0.0685 
CYP3A4 
cytochrome P450, family 3, 
subfamily A, polypeptide 4 1.028747 0.562043 0.0757 
IGF1 
insulin-like growth factor 1 
(somatomedin C) -1.09665 0.733641 0.0962 
CD36 
CD36 molecule 
(thrombospondin receptor) 1.034515 0.797892 0.1013 
GP2 
glycoprotein 2 (zymogen 
granule membrane) -1.00742 0.812039 0.1013 
TTPA 
tocopherol (alpha) transfer 
protein -1.00494 0.942894 0.1148 
*Log2 fold change 
†
Estimated for gene list individually 
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Table A.7 Selenium-responsive gene list results of analysis of differential 
expression in GOLD Stage 2/3/4 lung tissue compared to GOLD 0/1 lung 
tissue 
 
Gene Symbol Gene name Fold change* Raw p-value FDR q-value
†
 
NR2F1 
nuclear receptor subfamily 2, 
group F, member 1 1.541015 0.002575 0.0347 
SELT selenoprotein T -1.17592 0.003286 0.0347 
P4HA1 
prolyl 4-hydroxylase, alpha 
polypeptide I -1.3145 0.006994 0.0347 
MS4A1 
membrane-spanning 4-
domains, subfamily A, member 
1 2.247885 0.007846 0.0347 
GNGT2 
guanine nucleotide binding 
protein (G protein), gamma 
transducing activity 
polypeptide 2 -1.39245 0.008919 0.0347 
GSTO1 
glutathione S-transferase 
omega 1 -1.2314 0.009757 0.0347 
HOMER3 homer homolog 3 (Drosophila) 1.153352 0.038264 0.1048 
CDH5 
cadherin 5, type 2 (vascular 
endothelium) 1.43305 0.04402 0.1048 
PTGER2 
prostaglandin E receptor 2 
(subtype EP2), 53kDa -1.2226 0.047528 0.1048 
TGFA 
transforming growth factor, 
alpha -1.08058 0.052575 0.1048 
IGF1R 
insulin-like growth factor 1 
receptor 1.150651 0.057878 0.1048 
SELK selenoprotein K -1.11716 0.058934 0.1048 
DPYSL2 dihydropyrimidinase-like 2 1.104713 0.07002 0.1149 
GPX2 
glutathione peroxidase 2 
(gastrointestinal) 1.131863 0.078732 0.1200 
FOSL1 FOS-like antigen 1 -1.71855 0.088596 0.1260 
GLRX glutaredoxin (thioltransferase) -1.1981 0.100734 0.1343 
SORT1 sortilin 1 -1.1286 0.112609 0.1413 
SELP 
selectin P (granule membrane 
protein 140kDa, antigen CD62) 1.467479 0.129206 0.1438 
GPX7 glutathione peroxidase 7 1.222907 0.138196 0.1438 
SEPHS1 selenophosphate synthetase 1 1.128556 0.145634 0.1438 
G6PD 
glucose-6-phosphate 
dehydrogenase -1.16261 0.148141 0.1438 
TXNRD1 thioredoxin reductase 1 -1.19544 0.148331 0.1438 
GRIK3 
glutamate receptor, ionotropic, 
kainate 3 -1.06849 0.19071 0.1766 
GPX3 
glutathione peroxidase 3 
(plasma) 1.20025 0.198716 0.1766 
PXN paxillin 1.061279 0.220157 0.1811 
TXN thioredoxin -1.09975 0.220748 0.1811 
SEPP1 selenoprotein P, plasma, 1 1.050406 0.359795 0.2767 
GPX1 glutathione peroxidase 1 -1.09406 0.36321 0.2767 
GPX4 
glutathione peroxidase 4 
(phospholipid 
hydroperoxidase) -1.06856 0.384233 0.2827 
TXNRD2 thioredoxin reductase 2 -1.06666 0.398755 0.2836 
ELF3 
E74-like factor 3 (ets domain 
transcription factor, epithelial-
specific ) -1.38783 0.426537 0.2935 
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Table A.7 Selenium-responsive gene list results of analysis of differential 
expression in GOLD Stage 2/3/4 lung tissue compared to GOLD 0/1 lung 
tissue (continued) 
 
Gene Symbol Gene name Fold change* Raw p-value FDR q-value† 
SNAP23 
synaptosomal-associated 
protein, 23kDa 1.057051 0.492559 0.3284 
MGST1 
microsomal glutathione S-
transferase 1 -1.06892 0.55232 0.3571 
NR5A1 
nuclear receptor subfamily 5, 
group A, member 1 -1.02478 0.63119 0.3960 
GRIK1 
glutamate receptor, ionotropic, 
kainate 1 1.017431 0.747055 0.4396 
GSTK1 
glutathione S-transferase 
kappa 1 1.018051 0.758947 0.4396 
SEPW1 selenoprotein W, 1 -1.02027 0.762453 0.4396 
GSTA1 
glutathione S-transferase 
alpha 1 1.17028 0.824007 0.4516 
NR4A2 
nuclear receptor subfamily 4, 
group A, member 2 1.116419 0.825587 0.4516 
GSR glutathione reductase -1.00589 0.946505 0.5048 
GSS glutathione synthetase 1.000382 0.994643 0.5074 
FOXC1 forkhead box C1 -1.00031 0.998918 0.5074 
*Log2 fold change 
†
Estimated for gene list individually 
 
 
